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Thesis Abstract 
Previous findings showed that mild chronic restraint stress causes motor 
impairments in rats. These behavioural impairments might be related to molecular 
changes in brain areas that regulate motor functions, such as the cerebellum. Little is 
known about the role of the cerebellum in stress-induced behavioural alteration. We 
hypothesized that alteration in animal behaviour after chronic restraint stress is due to 
brain-specific changes in miRNA and proteins encoding gene expression. Our results 
revealed that expression of three miRNAs and 39 mRNAs was changed significantly after 
two weeks of stress. Furthermore, we verified one putative target for one of the changed 
miRNAs and expression of four randomly selected genes. Changes in gene expression 
disappeared after two weeks of recovery from stress. These findings provide a novel 
insight into stress-related mechanisms of gene expression underlying altered behavioural 
performance. The observations bear implications for the prevention and treatment of 
stress-related disorders and disease. 
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INTRODUCTION 
Although the term physiological stress is ubiquitously used today, it was not until 
1914 when Walter Bradford Cannon first described the psychophysiology of the stress 
response (Quick and Spielberger, 1994). Cannon pioneered the study of stress by 
investigating the alarm and emergency components of the stress response and the role of 
the sympathetic nervous system in adaptation (Neylan, 1998). Cannon defined stress as 
“the body’s ability to prepare itself instantaneously to respond to physical threat” 
(Cannon, 1914). A major contribution to the empiric paradigm of stress was made by 
Hans Selye, who described his concept of the General Adaptation Syndrome in 1936 
(Selye, 1936). In this work Selye provided a description of physiological and 
morphological changes in the adrenal gland, the thymus, spleen and other lymphoid 
tissue, and gastric ulcerations, which were due to the response of an organism to the 
negative (distress) or positive (eustress) aspects of stress (Selye, 1936). It was actually 
Selye who introduced the term stress from engineering to describe this complex 
phenomenon. There are many definitions of stress, but most of them originate from the 
so-called classical definition provided by Selye (Selye, 1936). According to Selye, stress 
is defined as “the nonspecific response of the body to any demand made on it” (Selye, 
1936). Since the beginning of the 21
st
 century stress became an important area of 
multidisciplinary research and many mechanisms and components of stress have been 
described.  
 
 Stress affects almost all functional systems of the organism including the brain 
through cascades of hormonal reactions and activation of the autonomic nervous system. 
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Psychological challenges that we are experiencing on a daily basis are among the most 
powerful stimuli to induce neuroendocrine, autonomic and behavioural changes (Kovacs 
et al., 2005). These in turn could facilitate the onset and progression of many diseases. 
Variability in the stress response depends on the genetic and epigenetic background of 
each individual (DeRijk et al., 2010). Since 1914 an abundance of data suggested that 
stress can induce lasting molecular and physiological changes in the brain and its output, 
behaviour. The brain represents a central regulator which controls the behavioural and 
physiological responses to stressful events. In turn, brain function is controlled by 
positive or negative feedback mechanisms (McEwen, 2007). Moreover, chronic stress 
affects the expression level of genes, including brain-derived neurotrophic factor, cAMP-
response-element binding protein, serotonin receptors and components of the 
hypothalamic-pituitary-adrenal (HPA) axis in experimental models (Alfonso et al., 2005), 
thus contributing to lasting changes in physiology and behaviour. 
 
 At the same time an important part of gene expression regulation is orchestrated 
by epigenetic components, such as DNA methylation, histone modification, chromosome 
remodeling, and small non-coding RNAs (microRNA, miRNA). Chronic stress may be 
an important contributing factor not only to genetic, but also to epigenetic changes in the 
brain. The understanding of the interaction between genetic and epigenetic components in 
the brain under a stressful condition can provide an insight into pathogenic processes that 
contribute to neurological diseases. For example, recent studies have shown that chronic 
stress is an important factor in the development of hypertension, gastrointestinal 
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disorders, immune suppression, reproductive dysfunction and mental disorders (McEwen, 
2004, Sandi and Pinelo-Nava, 2007). 
 
The chronic restraint stress paradigm in rodents is a model to study the effects of 
psychological stress. Chronic restraint stress causes different changes in the organism on 
the behavioural, physiological, and molecular levels. Stress-induced changes in the brain 
involve the hypothalamus, hippocampus, striatum, pituitary, pineal gland, amygdala, and 
spinal cord.  
 
Preliminary data suggest that twenty minutes of daily restraint stress during two 
weeks causes behavioural impairments in motor function in rats (Jadavji and Metz, 
2008). Observed behaviour impairments might be caused by changes in the brain areas 
that regulate motor functions, such as motor cortex and cerebellum. The role of motor 
cortex in motor function is well studied, while functions of the cerebellum in motor 
behavioural impairments remain to be investigated. To our knowledge, there are no data 
on mRNA and miRNA expression in the cerebellum after restraint treatment. We 
hypothesized that alteration in animal behaviour after chronic restraint stress is due to 
different cerebellum-specific changes in miRNA and protein encoding gene expression.  
 
The major purpose of this research was to quantify the extent of epigenetic 
adaptation to a chronic mild stressor in the cerebellum using a rat model. mRNA and 
miRNA expression profiles were assayed in animals exposed to two weeks of daily 
restraint stress and two weeks after cessation of stress in comparison to no-stress controls. 
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The results revealed that expression of 39 genes and three miRNAs was changed after 
two weeks of restraint treatment. Furthermore we verified one putative target for one of 
the changed miRNAs and expression of four randomly selected genes. These data suggest 
that even a very mild stressor can cause molecular changes in the brain, which might play 
an important role in the onset and progression of neurological diseases.  
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2. LITERATURE REVIEW 
2.1. Physiological, molecular, and behavioural correlates of stress 
Different components of the central nervous system (hypothalamus, pituitary, 
brain stem) and peripheral components (efferent limbs of sympathetic nervous system, 
adrenal medulla and adrenal cortex) become active in response to an internal or an 
external stressor (Weinstock, 2010). It was shown that stress and stress hormones could 
alter neurogenesis in the adult mammalian brain (Gould et al., 1997, Kirby and Kaufer, 
2010). According to Selye, adrenocorticotrophic hormone (ACTH) is released from the 
pituitary gland in response to stress, followed by subsequent secretion of glucocorticoids 
from the adrenal glands. Abundant research was done since that time which showed that 
function and regulation of the HPA axis is much more complex and involves the brain on 
many levels. The paraventricular nucleus (PVN) of the hypothalamus releases 
corticotropin-releasing hormone (CRH) and arginine-vasopressin (AVP) that activate the 
pituitary gland, which in turn, releases ACTH thus stimulating the adrenal glands. In 
response to activation the adrenal glands release glucocorticoids into the bloodstream. 
Aside from the brain’s prominent feedback mechanisms in response to circulating 
glucocorticoids, central effects also involve changes in gene expression, protein synthesis 
and their storage, emphasizing a crucial role of the brain in the temporary and permanent 
consequences of stress (Levine, 2005). Thus, glucocorticoids through their respective 
receptors in the brain, the mineralocorticoid and glucocorticoid receptors, are able to 
participate in multifarious genomic and nongenomic responses throughout the organism 
(Welberg and Seckl, 2001, Herman et al., 2003, Morris, 2007); see reviews by (de Kloet 
et al., 2005, McEwen, 2007, McEwen and Gianaros, 2010).  
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The effects of the stress response can be harmful or beneficial, depending on the 
type and intensity of stress, its duration, individual differences in coping with stress, 
duration and timing of stress hormone exposure (Sapolsky et al., 2000, Joels et al., 2007). 
The main responsibility for the outcome of the stress response on a hormonal level is 
given to glucocorticoids (cortisol in primates and corticosterone in most rodents, 
hereafter abbreviated as CORT) (Sapolsky, 1999, Sorrells et al., 2009). CORT plays a 
protective role by preventing the stress response system from overshooting (Munck et al., 
1984, Sapolsky et al., 2000). Excessive amounts of CORT are beneficial or harmless for a
 
few days, but can lead to fatal consequences if prolonged (Sapolsky et al., 2000). 
Dysregulation in the action of glucocorticoids was implicated in increased susceptibility 
to many stress-related brain diseases and other pathological conditions (de Kloet et al., 
2005, de Kloet et al., 2009, Oitzl et al., 2010). 
Stress impairs the body’s defenses against agents such as bacteria, viruses, and 
toxins, thus making the body more susceptible to disease (Sapolsky, 2002). Psychological 
types of stress modulate stress physiology and can trigger a stress response in the absence 
of physical damage and homeostatic imbalance (Sapolsky, 2002). According to Sapolsky, 
the stress response is ideal for coping with short-term physical stressors. The system did 
not evolve, however, to deal with chronic activation, and therefore a long-term stress 
response, which is usually not activated for a physiological reason, may eventually result 
in stress-related disease (Sapolsky, 2000b, 2002).  
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The stress response can be defined as a physiological and behavioural adaptation 
to the emotional or physical threats, either actual or imagined (de Kloet et al., 2009). 
Stress and stress hormones are known to cause impairments in working memory function 
in both humans (Kirschbaum et al., 1996, de Kloet et al., 1999, McEwen, 2000, Lupien et 
al., 2005) and animals (Diamond and Park, 2000, Cerqueira et al., 2007), enhance or 
impair learning, memory consolidation and memory retrieval (Overmier and Seligman, 
1967, Faraji et al., 2009). Other behavioural changes caused by stress in rodents include 
inhibition of exploratory activity (Weiss et al., 1980) and impaired gross and skilled 
motor function (Jadavji and Metz, 2008). Nevertheless, behavioural changes in stressed 
animals may also occur in the absence of elevated CORT levels suggesting that other 
mechanisms, such as emotional responses to a stressor, may modulate behaviour (Metz et 
al., 2005). 
 
Furthermore, chronic exposure to stress can lead to a suppression of cell 
proliferation (Czeh et al., 2002, Pham et al., 2003), and hippocampal atrophy (Watanabe 
et al., 1992, Magarinos and McEwen, 1995b, Magarinos et al., 1996, Sapolsky, 2000a). 
Accordingly, stress also affects recovery from brain damage, such as diminishing 
compensation in a rat model of stroke (Kirkland et al., 2008) and exaggerating neural loss 
in a rat analogue of Parkinson’s disease (Smith et al., 2008). 
 
Changes in behaviour and recovery from brain damage are related to changes on 
the molecular level. These include changes in gene expression, followed by altered 
protein and metabolite levels (Coirini et al., 1985). Exposure to chronic restraint stress in 
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rodent models, for instance, leads to changes in gene expression in different brain areas 
including frontal cortex (Lee et al., 2006), prefrontal cortex (Chen et al., 2008), 
hypothalamus (Harris et al., 2006, Lee et al., 2006, Chen et al., 2008), hippocampus 
(Zuena et al., 2008), pineal gland (Dagnino-Subiabre et al., 2006), and the amygdala 
(Kim and Han, 2006). Changes in gene expression as well as RNA levels are regulated by 
many parameters including epigenetic mechanisms. These involve changes in the 
methylation pattern, histone modifications, altered chromatin structure and production of 
miRNA. Recent studies showed a strong correlation between DNA methylation and 
behaviour (Colvis et al., 2005, Champagne et al., 2006). 
In this chapter we discussed physiological, molecular, and behavioural correlates 
of stress. The next chapter covers the role of stress in early-life experiences. 
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2.2. Early-life stress versus late-life influences 
During the life-span some periods appear to be more critical than others in terms 
of sensitivity to stress. A particularly stress-sensitive period is the perinatal period (in 
humans, it is an interval approximately from the 28th week of gestation to the 28th day 
after birth). Animal models indicate that events during pregnancy and early-life mother-
infant interactions can permanently alter the stress-regulating systems in the offspring 
(Oitzl et al., 2010). Recent research has demonstrated that long-lasting impact of adverse 
experience early in development on behaviour later in life results from long-term changes 
in gene expression mediated by epigenetic components (Shepard et al., 2009). 
 
Among other sensitive developmental periods which might play an important role 
in the establishment of epigenetic marks is the slow growth period (SGP) before the 
prepubertal peak in growth velocity. Human epidemiological data shows that different 
food availability during the SGP alters the transgenerational response, such as longevity 
and incidence of cardiovascular disease and diabetes (Kaati et al., 2002, Kaati et al., 
2007). 
 
The social environment and endocrine experiences early in life might lastingly 
influence brain function and modulate the adult behavioural phenotype (Crews, 2008). 
Early-life experiences and genetic background are important factors that can cause an 
imbalance in stress-regulating systems, which lead to establishing a phenotype vulnerable 
to later-life stressors (Oitzl et al., 2010). Maternal care influences gene expression, 
behavioural and HPA axis responses in the offspring, thus predetermining health outcome 
10 
 
in the adult offspring possibly through various generations (Meaney et al., 2007, Weaver, 
2009). Work in rats has revealed that the effects of maternal care are associated with 
epigenetic regulation of glucocorticoid receptor expression in the brain (Weaver et al., 
2005, Weaver et al., 2007). Early-life stress was shown to cause memory alterations in 
mice and was accompanied by an increase in AVP expression, which, in turn, was 
associated with sustained DNA hypomethylation of multiple CpG residues of the Avp 
enhancer region (Murgatroyd et al., 2009).  
In this chapter we discussed the impact of early-life experience on health and 
disease. In the next chapter we will focus on the role of stress in neurological disease. 
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2.3. Stress as an important contributing factor to neurological disease 
An important concept of stress physiology is that turning on the stress response 
for too long is likely to lead to the development of a chronic disease (Sapolsky, 2000b) 
(Fig. 2.1). 
 
Figure 2.1. Schematic representation of stress outcomes. 
 
The factors which are involved in the onset and development of 
neurodegenerative disorders are begun to be identified, but the mechanisms of 
pathogenesis still remain unclear. Nevertheless, different neurological disorders share 
common risk factors, which may lead to synaptic dysfunction, neuronal degeneration and 
cell death, thus contributing to the disease. These common factors include lack of 
physical activity, lack of dietary folate, oxidative stress associated with aging, metabolic 
impairment, dysregulation of ion homeostasis, DNA damage, apoptosis, and 
excitotoxicity (Mattson, 2003). On the other hand, these factors could cause alterations in 
epigenetic regulation in the organism, thus they might impact onset and development of 
various neurodegenerative diseases through mechanisms of epigenetic response. Another 
important factor which might play a key role in the epigenetic response and the 
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development of pathological processes in the brain is stress, which together with other 
agents may lead to the onset and progression of Alzheimer’s disease (AD), Parkinson’s 
disease (PD), Huntington’s disease (HD), multiple sclerosis (MS) or development of 
stroke (Fig. 2.2). 
 
 
 
  Figure 2.2. Role of environmental factors in the epigenetic response in the brain 
and neurological diseases. Different environmental factors such as nutrition, physical and 
mental activity, maternal care and early life experience, exposure to chronic stress, 
chemicals and radiation, and pathogens can alter the epigenetic pattern in the brain. These 
processes in turn may promote neuronal degeneration and contribute to the onset and 
development of different neurological conditions, including Alzheimer’s disease (AD), 
Parkinson’s disease (PD), Huntington’s disease (HD), multiple sclerosis (MS), and 
stroke.  
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2.4. Epigenetics in neurobiology 
The completion of the Human Genome Project in 2003 was a hallmark event in 
biology, however many mysteries in such a complex biological process as gene 
expression regulation remain still unrevealed. The rise of a new discipline of epigenetics 
in recent decades promises to answer some of these questions. The understanding of how 
the environment influences genetics evolves through centuries, from Lamarck and 
Darwin till nowadays, after the term epigenetics was coined by Conrad Waddington in 
the 1940s. Epigenetics can be defined as the study of heritable changes in gene 
expression that are not caused by changes in the nucleotide sequence of the DNA. 
Modifications in the epigenome play a vital role in many biological processes and 
molecular mechanisms in the organism. The main components of epigenetic regulation 
are DNA methylation, histone modification, chromatin remodeling, and non-coding 
RNAs. The recognition of the role of epigenetics in human disease started in oncology, 
but now it is extended to many other disciplines (Urdinguio et al., 2009). Recent studies 
suggest that epigenetic mechanisms might play an important role in the mediation of 
enduring changes in brain function (Darnaudery and Maccari, 2008). Research in the last 
decades highlighted the role of epigenetic regulation in many processes in the nervous 
system, such as neuron development and function, neuronal plasticity, and memory 
formation, raising the question of a possible role of epigenetics in neurological disease 
etiology. Current research is focused on the role of epigenetic components in 
neurodegenerative diseases, such as Alzheimer’s disease, Parkinson’s disease, and 
Huntington’s disease, suggesting its possible role in neuroprotection. 
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2.4.1. DNA methylation 
DNA methylation is part of the covalent structure of the DNA and in eukaryotes it 
consists of the covalent addition of a methyl group at the 5’-position of cytosines (Razin 
and Riggs, 1980). In mammals, DNA methylation occurs mostly at cytosine-phosphate-
guanine sites (CpG sites) and is associated with untranscribed chromatin and gene 
silencing, whereas active chromatin is generally associated with hypomethylated DNA 
(Kornberg, 1974, Razin and Riggs, 1980). Other functions of DNA methylation include 
regulation of genome stability through silencing repetitive elements, role in chromatin 
structure, genomic imprinting, inactivation of the X chromosome, and protection of DNA 
from degradation by nucleases. DNA methylation patterns carry the information about 
the regulation of gene expression and could be transmitted to the next generation. First 
molecular model for heritability of gene activation during development by DNA 
methylation was proposed by Robin Holliday and colleagues (Holliday and Pugh, 1975, 
Crews, 2008). 
 
The process of establishing and maintaining a DNA methylation pattern is 
complex and involves the interaction between methyltransferases and methyl-CpG 
binding proteins (MBDs). MBDs are the proteins that read and interpret the information 
of methylation patterns. For many years it was thought that DNA methylation is 
extremely stable and irreversible and that changes in DNA methylation patterns might 
occur only during critical periods in embryogenesis (Razin and Riggs, 1980). The new 
data suggest that DNA methylation is dynamic (Bhattacharya et al., 1999, Weaver et al., 
2004, Levenson et al., 2006, Miller and Sweatt, 2007). DNA methylation patterns are 
15 
 
actively maintained by DNA methyltransferases (DNMTs), which catalyze the transfer of 
a methyl group from the methyl donor S-adenosylmethionine onto the 5’ position of the 
cytosine ring (Adams et al., 1979, Van Emburgh and Robertson, 2008). Demethylation 
events may occur in the absence of dNTPs (Szyf et al., 2008), but their exact mechanisms 
still need to be determined (Reik, 2007). According to the Szyf group DNA methylation 
patterns represent a balance of methylation and demethylation reactions, which provide a 
platform for gene-environment interaction (Ramchandani et al., 1999).  
 
2.4.2. DNA methylation in neurobiology 
During brain development DNA methylation is believed to be important in 
regulating the proliferation of neural stem cells and their differentiation into neurons and 
glial cells (Mattson, 2003). Methylation of DNA in the brain is catalyzed by three main 
enzymes, DNMT1, DNMT3a, and DNMT3b. DNMTs are expressed throughout neural 
development and promote neuronal survival and plasticity, thus influencing stress 
responses in the brain (Klose and Bird, 2006, Ooi et al., 2007, Mehler, 2008). MBDs 
were shown to play an important role in brain development and cognitive functions such 
as learning and memory (Feng et al., 2007, Chahrour et al., 2008, Mehler, 2008).  
 
A growing body of research extends the function of DNA methylation beyond the 
developing nervous system. DNA methylation was shown to be important in neuronal 
apoptosis in the process of brain maturation (Yakovlev et al., 2010). Feng et al. (2010) 
showed that Dnmt1 and Dnmt3a are required for synaptic plasticity, learning and 
memory in adult CNS neurons (Feng et al., 2010). Recent data suggest an involvement of 
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DNA methylation processes in CNS repair (Iskandar et al., 2010). Iskandar and 
colleagues have shown that axonal regeneration after spinal cord and sciatic nerve injury 
relies on the integrity of DNA methylation pathways (Iskandar et al., (2010). Their study 
demonstrated a correlation between regeneration after injury, spinal cord DNA 
methylation and the expression of the de novo DNA methyltransferase enzymes Dnmt3a 
and Dnmt3b, but not Dnmt1. Research in the last decades has shown that DNA 
methylation patterns are altered in various pathological conditions of the nervous system 
(McGowan et al., 2008b, Feng and Fan, 2009). 
 
2.4.3. Chromatin remodeling and histone modification  
Chromatin remodeling and histone modifications play a key role in the 
accessibility of the nucleosome to the transcription machinery, and thus in gene silencing. 
The level of gene expression depends on different factors, including modifications in the 
histone N-terminal tails by methylation, acetylation, phosphorylation, SUMOylation, and 
ubiquitination. The first histone modification - lysine methylation - was reported by 
Murray in 1964 (Murray, 1964). This was followed by the discovery of other histone 
modifications, such as serine phosphorylation (Kleinsmith et al., 1966), lysine acetylation 
(Gershey et al., 1968, Vidali et al., 1968), ubiquitination and ADP-ribosylation  
(Goldknopf and Busch, 1975, Ueda et al., 1975)., 1975), and SUMOylation (Shiio and 
Eisenman, 2003) (for more details see (Sims et al., 2008)). 
 
The basic structural subunit of chromatin is the nucleosome, which consists of 
DNA, wrapped around an octamer, and formed by the histone proteins, termed H1, H2A, 
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H2B, H3 and H4 (Kornberg, 1974). Histone modifications are catalyzed by histone 
modification enzymes, including histone acetyltransferases (HAT), histone deacetylases 
(HDAC), histone methyltransferases (HMT) and histone demethylases. A change in a 
“histone code”, or specific pattern of histone modifications could result in gene activation 
or silencing (Jenuwein and Allis, 2001). Despite the above mentioned role in gene 
silencing, there is a controversy in the literature, whether nucleosome modifications 
should be considered as epigenetic changes, since they lack the fundamental epigenetic 
property of self-propagation (Ptashne, 2007). 
 
2.4.4. Chromatin remodeling and histone modification in neurobiology 
Understanding the concept of chromatin remodeling may provide an insight of 
how stable changes in gene expression in the brain produce long-lasting changes in 
behaviour (Colvis et al., 2005). Increasing evidence indicates that changes in the 
chromatin structure occur not only during development, but also in mature neurons 
(Tsankova et al., 2007, Renthal and Nestler, 2008). Neuronal signaling appears to be 
strongly regulated by addition and removal of histone acetylation, histone and DNA 
methylation (Renthal and Nestler, 2008). Recent studies showed that neuronal levels of 
monoacetylated H4 decrease progressively during aging, whereas levels of acetylation of  
non-histone proteins may increase in neurons during development and with age (Mattson, 
2003).  
 
It has been shown that chromatin remodeling via post-translational modification 
of histone proteins, primarily histone H3 phosphorylation and acetylation, is important in 
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the formation of long-term memory (Alarcon et al., 2004, Korzus et al., 2004, Levenson 
et al., 2004, Gupta et al., 2010, Peleg et al., 2010). Some data suggest that histone 
methylation is actively regulated in the hippocampus and facilitates long-term memory 
formation, while deregulation of H4K12 acetylation may cause memory impairments in 
the aging mouse brain (Gupta et al., 2010, Peleg et al., 2010). Interestingly, it was shown 
recently that mammalian neurons have a specialized chromatin remodeling enzyme, 
histone lysine specific demethylase 1, suggesting its role in gene repression (Zibetti et al., 
2010). 
HDACs catalyze the removal of an acetyl group from the N-terminal tails of 
histone proteins, while histone acetyl transferases (HATs) catalyze the reverse reaction 
(Sleiman et al., 2009). The alteration in balance between HDAC and HAT functions can 
lead to cancer as well as to neurodegenerative disease (Hahnen et al., 2008). HDAC 
inhibitors have shown therapeutic efficacy in animal models of neurodegenerative 
diseases, including HD, PD, AD (Fischer et al., 2007, Abel and Zukin, 2008), suggesting 
a neuroprotective role. HDAC inhibitors are currently available for therapy for several 
neurological disorders. A protective role of HDACs was also implicated in a rodent 
stroke model (Faraco et al., 2006). Faraco and colleagues demonstrated that HDACs 
promotes expression of neuroprotective proteins within the damaged brain area (Faraco et 
al., 2006). 
 
2.4.5. Non-coding RNAs 
  Around 98% of transcribed genomic DNA are non-coding RNAs that do not 
function as messenger, transfer or ribosomal RNAs (Yu, 2008). miRNAs are small non-
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coding single-stranded RNA molecules approximately 22 nucleotides long, which can 
regulate gene expression via an RNA interference pathway by altering mRNA stability 
and translational initiation. Each miRNA can regulate thousands of different mRNA 
targets (Nelson et al., 2008). 
 
 miRNAs were first described in Caenorhabditis elegans (Lee et al., 1993, 
Wightman et al., 1993). Further research reported their involvement in many biological 
processes, such as cellular development, differentiation, proliferation, cell division, 
apoptosis, onset and progression of cancer and other diseases. The expression of miRNA 
molecules depends on different factors and can be regulated by other epigenetic agents, 
such as DNA methylation and chromatin structure (Saito and Jones, 2006). 
 
2.4.6. RNA-mediated gene silencing 
RNA-mediated gene silencing is an evolutionarily conserved process in which 
dsRNA molecules interfere with target genes and initiate a cascade of events that repress 
expression of target genes in a sequence-specific manner (Rodriguez-Lebron and 
Paulson, 2006). In animals, the double-stranded RNA-specific endonuclease Dicer 
produces two classes of small RNAs: miRNAs and small interfering RNAs (siRNAs). 
miRNAs function through attenuation of mRNA translation, whereas siRNAs direct RNA 
destruction via the RNA interference (RNAi) pathway (Hutvagner and Zamore, 2002). In 
order to inhibit translation, nucleotides 2-7 of the 5’ end of the guide strand of miRNA 
(seed sequence) must be of a perfect or near-perfect complementarity to the target 
sequence in the mRNA 3’UTR (Smalheiser and Torvik, 2006).  
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2.4.7. Non-coding RNAs in neurobiology 
 The expression of miRNAs is cell- and tissue-specific and miRNAs are 
particularly abundant in the brain (Kosik, 2006). Many miRNAs are expressed in a 
spatially and temporally controlled manner in the nervous system, suggesting that their 
regulation may be important in neural development and function (Barbato et al., 2009). 
Recent research showed that miRNAs play important roles in nervous system 
development and function, neurodegenerative and neuropsychiatric diseases as well as in 
brain cancer (Mehler and Mattick, 2006).  
 
 Evidence in the past years has indicated that miRNAs may be a contributing 
factor to aging-related neurodegenerative diseases (Colvis et al., 2005, Nelson and Keller, 
2007, Nelson et al., 2008). Schaefer et al. (2007) for instance demonstrated that 
substantial loss of  mature miRNA in the cerebellum of mice with knocked-out Dicer 
gene causes progressive neurodegeneration in a mouse model, suggesting that the same 
mechanism may be relevant in human neurodegenerative disorders (Schaefer et al., 
2007).  
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2.5. Role of epigenetic regulation in stress response and its influence on the 
development of neurological diseases 
2.5.1. Epigenetics of the stress response 
Resent research on epigenetic regulation of the stress response is mainly 
focused on the role of glucocorticoids. Growing evidence suggests that mineralocorticoid 
(MR) and glucocorticoid (GR) signaling in the brain might be regulated by epigenetic 
components (de Kloet et al., 2009). For instance, Uchida et al. (2008) compared the stress 
response in the Fisher 344 rat strain (which represent a stress-hyperresponsive strain) and 
the Sprague-Dawley strain. They reported that after two weeks of restraint stress Fisher 
344 rats had lower expression of GR protein but not mRNA in the hypothalamus. 
Authors also demonstrated that miR-18a was overexpressed in the hypothalamus in 
Fisher 344 rats as compared to Sprague-Dawley rats, and that miR-18a inhibits 
translation of GR mRNA in vitro. Their findings suggest that miR-18a regulation of GR 
translation could play a role in susceptibility of stress-related diseases (Uchida et al., 
2008). On the other hand, Vreugdenhil et al. (2009) demonstrated that miR-18 expression 
in the brain is 8-fold lower than what is needed in vitro to regulate the expression of GR 
protein, thus the role of miR-18 in the brain still needs to be investigated (de Kloet et al., 
2009, Vreugdenhil et al., 2009).  
 
Epigenetic effects of glucocorticoids, mainly through their role in early life 
experience, were well demonstrated by the Meaney and Szyf groups. They suggested that 
variations in maternal care might be responsible for the individual differences in stress 
reactivity across generations on a non-genetic basis (Francis et al., 1999). In particular, it 
was shown in a rodent model that the offspring of mothers that exhibit high level of pup 
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licking/grooming (LG) behaviour show an increased level of GR mRNA expression in 
the brain. The authors proposed that this mechanism is regulated by DNA methylation 
(Weaver et al., 2007). The Meaney and Szyf groups demonstrated that increased LG 
behaviour is associated with demethylation of the 5’ CpG site within the exon 17 of GR 
gene promoter region (Weaver et al., 2004). Moreover, they demonstrated that dietary 
methionine treatment reverses the stress response in the adult offspring of high LG 
mothers (Weaver et al., 2005). 
 
2.5.2. Neurological disease background  
Neurological diseases are disorders primarily affecting the nervous system. There 
are more than 600 nervous system disorders including stroke, epilepsy, head and spinal 
cord injury, Alzheimer's disease, Parkinson's disease, multiple sclerosis, Huntington’s 
disease and brain tumors. Here we will focus on some of the most known and best 
studied diseases.  
 
Ischemic stroke commonly results from occlusion of a major artery in the brain, 
which causes cell death in the affected area (Sims and Muyderman, 2010).  
 
Alzheimer's disease (AD) is a common form of dementia, which is characterized 
by cognitive, and in the advanced stage, by physical impairments. AD is a slowly 
progressive complex disease of the brain, the development and progression of which 
depends on many factors including genetic and environmental components. Although the 
formation of neuritic plaques and neurofibrillary tangles in the brain are associated with 
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AD (Tiraboschi et al., 2004), the causes of onset and progression of this disease remain 
poorly understood. 
 
Parkinson’s disease (PD) is a progressive neurological disorder characterized by 
the selective and progressive loss of dopaminergic neurons in the midbrain substantia 
nigra, which causes a large number of motor and non-motor impairments (Jankovic, 
2008, Sleiman et al., 2009). Near six million people worldwide have PD, and it affects 
1% of the population over 65 (Gasser, 2001, Abel and Zukin, 2008). 
 
Multiple sclerosis (MS) is an inflammatory autoimmune disorder, characterized 
by damage of myelin and axons in the brain and spinal cord (Compston and Coles, 2002, 
2008). 
 
Huntington’s disease (HD) is an autosomal, dominant, neurodegenerative disease, 
which affects about 3 in 100 000 individuals (Barbato et al., 2009). HD is characterized 
by incoordination, progressive involuntary movements, neuropsychiatric disturbancest, 
and cognitive decline (Montoya et al., 2006, Walker, 2007). HD is caused by a 
polyglutamine expansion in the 5′-coding region of the huntingtin (htt) gene (Bates, 
2001).  
 
The molecular mechanisms underlying the above mentioned disease onset and 
progression remain poorly understood (Sleiman et al., 2009), which leads to the absence 
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of effective cures. Therefore, up to date the above mentioned diseases have no known 
cure. 
 
In recent years a growing body of evidence suggests involvement of an epigenetic 
component, particularly an exciting therapeutic potential of HDAC inhibitors, which have 
shown broad efficiency in cellular and animal models of many diseases, including stroke, 
AD, PD, and HD (Ratan, 2009, Sleiman et al., 2009). 
 
2.5.3. Epigenetic mechanisms underlying neurodegenerative diseases 
Neurodegenerative diseases are diseases in which the nervous system 
progressively and irreversibly deteriorates. Recent studies suggest that neurodegenerative 
diseases are mediated by aberrant epigenetic mechanisms. Genes that are responsible for 
the inherited form of neurodegenerative disorders, encoding alfa-synuclein and Parkin in 
PD, presenilin-1, presenilin-2, Tau in AD and huntingtin in HD represent potential targets 
for epigenetic regulation. Genes encoding other proteins, involved in a complex cascade 
of chemical reactions, leading to the process of neurodegeneration still need to be 
identified. 
 
2.5.4. miRNA and neurodegenerative diseases 
The discovery of an association between miRNA deregulation and different 
neurological disorders opened a new area of research on neurodegenerative illnesses. 
miRNAs have been implicated in several neurologic disorders, including AD, PD, HD, 
and MS (Barbato et al., 2008, Maes et al., 2009, Otaegui et al., 2009). 
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Alteration in miRNA function and aberrant miRNA expression contributes to 
human disease and has a potential as disease biomarkers (Chang and Mendell, 2007, 
Maes et al., 2009). miRNA profiling in human patients with AD identified a number of 
miRNA up-regulated in peripheral blood mononuclear cells (Schipper et al., 2007), 
however, further investigations still need to be done to assess their potential as blood-
based diagnostic and prognostic biomarkers. 
 
Noncoding RNAs are also necessary for survival of neurons in PD and other 
neurological disorders (Hebert and De Strooper, 2007). Systemic increase in specific 
miRNAs may suppress various cellular functions in AD (Maes et al., 2009). miRNAs 
were proposed to be important in the molecular mechanisms implicated in MS, 
suggesting their role as candidate biomarker targets in MS (Otaegui et al., 2009). Work of 
Otaegui et al. (2009) suggests that  hsa-miR-18b and hsa-miR-599 may be involved at the 
time of relapse, while hsa-miR-96 may play a role in remission (Otaegui et al., 2009). 
 
Various miRNAs were reported to be altered in rodent models of AD (Table 2.1). 
Considering the fact that some miRNAs are highly conserved between mammals, while 
other are poorly conserved, additional research needs to be done in this area to determine 
whether all of these miRNAs are active in the human brain and have similar functions.   
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Table 2.1. miRNAs associated with neurodegenerative disorders. 
miRNA Brain area Status Disease The role in disease References 
miR-9 hippocampus ↑Up-
regulated 
AD in 
animal 
model 
Needs to be investigated (Lukiw, 2007) 
miR-128 Kim et al., 2007 
miR-15a Cortex ↓Down-
regulated 
Candidate binding sites 
in the 3’UTRs of beta 
site amyloid precursor 
protein (APP) cleaving 
enzyme (BACE) 
Barbato et al., 2009 
miR-
29b-1 
(Hebert et al., 
2008) 
miR-19b 
miR-9 Cortex ↓Down-
regulated 
Candidate binding sites 
in the 3’UTRs of BACE 
and PSEN1 
Barbato et al., 2009 
101 Cortex ↓Down-
regulated 
Candidate binding sites 
in the 3’UTR of APP 
Barbato et al., 2009 
15a 
106b 
Let-7 
miR-210 Cortex ↓Down-
regulated 
Seem to be unrelated to 
obvious targets 
Barbato et al., 2009 
miR-
181c 
 
miR-22 
miR-26b 
miR-363 
miR-93 
miR-9 Cerebrospinal 
fluid 
↓Down-
regulation 
Correlation to impaired 
neurogenesis and 
neuronal differentiation 
Barbato et al., 2009 
miR-132 Maes et al., 2009 
miR-423 hippocampus ↑Up-
regulated 
Modulate IDH2 
(isocitrate dehydrogenase 
2) expression and IDH2 
reduction is involved in 
oxidative stress in AD 
prefrontal cortex 
Barbato et al., 2009 
miR-98 cerebellum ↓Down-
regulation 
miR-107 Medial 
frontal cortex 
↓Down-
regulation 
Correlates with BACE1 
mRNA increase, miR-
107 modulates 
expression of BACE1 in 
cell culture 
(Wang et al., 2008) 
Motor cortex 
miR-34a Peripheral 
blood 
mononuclear 
cells  
↑Up-
regulation 
AD in 
human 
patients 
May repress neuronal 
and synapse function 
(Wang et al., 2008) 
miR-
181b 
May repress DNA repair 
and stress response 
Maes et al., 2009 
miR-
520h 
May play role in immune 
response, signal 
transduction 
miR-371 May repress 
mitochondria function 
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miR-
517* 
Could influence cell 
survival 
let-7f May repress immune and 
injury responses 
miR-
200a 
Might be important in 
stress response 
miR-
133b 
midbrain ↓Down-
regulated 
PD in 
human 
patients 
Differentiation and 
function of dopaminergic 
neurons 
(Kim et al., 2007) 
miR-433   Candidate binding site in 
the 3’UTR of FGF 20,  
modulate expression of 
alfa-syneclein, which 
might cause greater 
susceptibility to PD 
(Wang et al., 2008) 
 
2.5.5. Role of histone modification and chromatin remodeling in neurological 
diseases 
HDACs are considered to play a protective role in the brain (Jiang et al., 2008). 
Evidence from the past years has indicated that the balance between HATs and HDACs is 
impaired in many neurodegenerative conditions (Saha and Pahan, 2006). HDAC 
inhibitors are very promising for the therapy of neurodegenerative diseases (Fischer et al., 
2007). They have shown therapeutic efficacy in animal models of HD (Ferrante et al., 
2003) and stroke (Ren et al., 2004, Faraco et al., 2006). HDAC inhibitors have shown a 
protective effect against oxygen and glucose deprivation and against oxidative-stress-
induced cell death in vitro, which strongly suggests their potential in treatment for stroke 
patients (Sleiman et al., 2009). For a broader discussion of the role of HDAC inhibition in 
neurodegenerative diseases see Sleiman et al. (2009). 
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2.5.6. Role of methylation in neurological diseases 
Evidence from the study of monozygotic twins suggests that epigenetic rather 
than genetic factors might be responsible for differences in DNA methylation patterns in 
adult tissues (Fraga et al., 2005). Alteration in DNA methylation during embryogenesis 
and possibly during adult life can lead to stable changes in gene expression and 
development of different pathological conditions (Feinberg, 2007, McGowan et al., 
2008a). 
Several approaches are available to assess DNA methylation patterns in normal 
and disease-associated cells and tissues, but for neurological diseases, the few DNA 
methylation markers that have been identified so far require further confirmation 
(Urdinguio et al., 2009). Studies of cultured neurons have shown that alterations in 
methylation and acetylation can cause cell death, thus suggesting their role in the cascade 
of reactions leading to neurodegeneration (Mattson, 2003).  
 
Altered DNA methylation patterns were observed in AD, PD, and MS (Urdinguio 
et al., 2009). A high-throughput screening study in human cerebral cortex revealed two 
genes which are differently methylated in Alzheimer’s tissues, as compared to controls: 
S100a2 (S100 calcium binding protein A2) and Sorbs3 (sorbin and SH3 domain 
containing the 3 cell-adhesion protein) (Siegmund et al., 2007). Sorbs3 was 
hypermethylated, while analysis of S100a2 revealed a decrease in DNA methylation in 
Alzheimer patients as compared to control cases. Alteration in the methylation pattern of 
S100a2 and Sorbs3 might play a role in synaptic impairment in AD (Urdinguio et al., 
2009). Also, hypermethylation of the promoter region of Nep (neprilysin) gene in murine 
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cerebral endothelial cells was reported, suggesting its role in amyloid-beta accumulation 
in AD (Chen et al., 2009).  
Recent evidence suggests that alterations in DNA methylation might play a role in 
the mechanism of MS pathogenesis (Mastronardi et al., 2007). It was shown that DNA 
methylation of cytosine of the Pad2 promoter in the white matter from MS patients was 
one-third of the methylation level in normal brain tissue (Mastronardi et al., 2007). 
Findings by Mastronardi et al. (2007) demonstrated also 2-fold higher DNA demethylase 
activity in tissues from MS patients as compared to those of normal, or Alzheimer's, 
Huntington's and Parkinson's disease white matter. For a more detailed review on 
epigenetic mechanisms in other neurological diseases see Urdinguio et al. (2009).  
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3. THE MOLECULAR MECHANISMS UNDERLYING EPIGENETICS OF THE 
STRESS RESPONSE IN THE CEREBELLUM IN A RAT MODEL  
3.1. Materials and methods 
3.1.1. Animals 
Twenty-four male adult Long-Evans hooded rats, approximately 4 months old 
(weighing approximately 460 g at the beginning of the study), from Charles River 
Laboratories International, Inc (Wilmington, MA, US) were used. Animals were 
habituated to the local environment for a period of three weeks prior to the start of the 
experiment. The rats were housed in pairs in standard polycarbonate shoebox cages under 
a 12 h light/day cycle with lights on at 7:30AM. All procedures were performed in 
accordance with the Canadian Council for Animal Care guidelines and approved by the 
local animal welfare committee. 
 
3.1.2. Experimental groups 
Animals were randomly assigned to one of the following experimental groups: 
Two weeks of daily restraint stress (2WSTRESS, n=6), two weeks naive controls 
(2WCONTROL, n=6), two weeks of daily restraint stress + two weeks of recovery from 
stress (4WSTRESS, n=6), four weeks naive controls (4WCONTROL, n=6). 
 
3.1.3. Time course 
            The 2WSTRESS group was subjected to 14 days of restraint stress, while the 
4WSTRESS group received two weeks of recovery after two weeks of restraint 
treatment. Stressed and respective control animals were sacrificed immediately after the 
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last day of stress and after 14 days of recovery from stress (Fig. 3.1). Blood samples were 
collected at baseline, on the first and last day of stress treatment, and on the last day of 
recovery after stress. 
 
 
Figure 3.1. Time course of the experimental manipulations. 
 
3.1.4. Physiological manipulations and stress procedure 
3.1.4.1. Chronic restraint stress procedure 
Animals were placed individually into transparent adjustable length Plexiglas 
tubes (diameter 8 cm, length 20 cm) for 20 minutes daily. The tube maintained the animal 
in a standing position. Small holes in the front of the tube allowed for ventilation. 
Restraint took place each day at the same time in the morning hours and in a room 
different from the colony room (Fig. 3.2). 
 
3.1.4.2. Blood sampling 
Blood samples were collected between 08:30AM and 11:00AM in order to 
minimize effects of plasma corticosterone circadian variations (D'Agostino et al., 1982). 
Samples were collected approximately 30 minutes after initiation of restraint stress (Metz 
et al., 2005). Rats were anesthetized with 4% isoflurane in 30% oxygen. Syringes and 
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butterfly catheters were rinsed with heparin prior to use for blood sampling. An average 
of 0.6 ml of blood was collected from the tail vein using a butterfly catheter. The sample 
was centrifuged at 4000 rpm for 10 minutes. After centrifugation plasma was collected 
and stored at -20 ˚C. Plasma corticosterone levels were determined by a corticosterone 
EIA Kit (Cayman Chemical Company, Ann Arbor, MI, USA). 
  
3.1.5. Corticosterone enzyme immunoassay (EIA) 
Quantification of corticosterone in plasma samples was performed with the 
Corticosterone EIA Kit according to the manufacturer’s instructions (Cayman Chemical 
Company, Ann Arbor, MI, USA). For the assay plasma samples were extracted three 
times with four volumes of methylene chloride and dried under a stream of nitrogen. The 
extracts were dissolved in EIA buffer in a volume which is equal to the initial sample 
volume. In a 96-well plate 100 µl of EIA buffer were added to Non-Specific Binding 
(NSB) wells, and 50 µl of EIA buffer were added to Maximum Binding (B0) wells. 50 µl 
of S1-S8 corticosterone EIA standards (5,000, 2,000, 800, 320, 128, 51.2, 20.5, and 8.2 
pg/ml, accordingly) were added in duplicates into corresponding wells on the plate. Two 
dilutions of each sample (50 µl) were added in triplicate into corresponding wells. Then 
50 µl of Corticosterone AChE Tracer was added to each well except the Total Activity 
(TA) and the Blank (Blk) wells, and 50 µl of Corticosterone EIA Antiserum was added to 
each well except the TA, Blk, and NSB wells. The plate was covered with plastic film 
and incubated for two hours at room temperature on an orbital shaker. After incubation 
wells were washed five times with 100 µl of wash buffer. Thereafter 200 µl of Ellman’s 
Reagent were added to each well, and 5 µl of tracer to the TA well. The plate was 
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covered with plastic film and incubated on an orbital shaker in the dark to allow optimum 
development. The plate was read at a wavelength of 412 nm. Calculations and data 
analysis were performed using the original Cayman spreadsheet. 
 
3.1.6. Brain tissue dissection and RNA extraction 
The rats were deeply anaesthetized with pentobarbital (WDDC, Edmonton, AB, 
Canada). After vital signs were discontinued animals were rapidly decapitated. Brains 
were rapidly removed. The brains of four animals from each group were used for 
dissection of cerebellum, frontal cortex and hippocampus. The brains of two animals 
from each group were flash-frozen. Dissected cerebellum was used for DNA/RNA 
extractions. 
 
3.1.7. DNA/RNA extractions 
The DNA/RNA isolation was performed using Trizol reagent (Invitrogen, 
Carlsbad, CA, USA) according to manufacturer instructions. The samples were treated 
with DNase I (Invitrogen, Carlsbad, CA, USA) according to manufacturer’s instructions 
and stored at -80°C. DNA and RNA were dissolved in DNase/RNase-free water (NEB, 
Ipswich, MA, USA).  
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Figure 3.2. Restraint stress procedure. Representative picture of restraint stress treatment. 
Male Long-Evans rats were placed into transparent plastic tubes for 20 minutes each day.   
 
3.1.8. Plasmid DNA purification 
Plasmid DNA was purified from overnight culture (20 ml LB medium 
supplemented with corresponding antibiotics) using the QIAprep Spin Miniprep Kit 
(Qiagen, Valencia, CA, USA). 
 
3.1.9. cDNA synthesis 
cDNA synthesis was performed using the RevertAid
TM
 H Minus First Strand 
cDNA Synthesis Kit (Fermentas, Barlington, ON, Canada). For the reaction 4.6 µg of 
total RNA, 1 unit of Ribolock RNase inhibitor, 10 mM dNTPs, oligo(dT18) primers, and 
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5x reaction buffer were used. The mix was incubated for 1 h at 42˚C and heat inactivated 
for 5 min at 70˚C. 
 
3.1.10. miRNA microarray expression analysis 
Tissue from three animals per group was used for the analysis. Total RNA was 
extracted from the cerebellum. The miRNA microarray analysis was performed by LC 
Sciences (Houston, TX, USA; www.lcsciences.com). The assay used from 2 to 5 µg of 
the total RNA sample, which was fractionated by size using a YM-100 Microcon 
centrifugal filter (Millipore, Billerica, MA, USA) and the small RNAs (< 300 nt) isolated 
were 3’-extended with a poly(A) tail using poly(A) polymerase. An oligonucleotide tag 
was then ligated to the poly(A) tail for later fluorescent dye staining. Two different tags 
were used for the two RNA samples in dual-sample experiments.  
 
Hybridization was performed overnight on a µParaflo microfluidic chip (LC 
Sciences, Houston, TX, USA) using a micro-circulation pump. On the microfluidic chip, 
each detection probe consisted of a chemically modified nucleotide coding segment 
complementary to the target miRNA (from miRBase, Welcome Trust Sanger Institute, 
Cambridge, UK; http://microrna.sanger.ac.uk/sequences/) or control RNA and a spacer 
segment of polyethylene glycol to extend the coding segment away from the substrate. 
The detection probes were made by in situ synthesis using PGR (photogenerated reagent) 
chemistry. The hybridization melting temperatures were balanced by chemical 
modifications of the detection probes. Hybridization used 100 µL 6xSSPE buffer (0.90 M 
NaCl, 60 mM Na2HPO4, 6 mM EDTA, pH 6.8) containing 25% formamide at 34°C. 
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After hybridization detection fluorescence labeling using tag-specific Cy3 and Cy5 dyes 
was performed. Hybridization images were collected using a laser scanner (GenePix 
4000B, Molecular Devices, Sunnyvale, CA, USA) and digitized using Array-Pro image 
analysis software (Media Cybernetics, Bethesda, MD, USA). Data were analyzed by first 
subtracting the background and then normalizing the signals using a LOWESS filter10 
(Locally-weighted Regression). For two-color experiments, the ratio of the two sets of 
detected signals (log2 transformed, balanced) and p-values of the t-test were calculated; 
differentially detected signals were those with less than 0.01 p-values (information 
provided by Jason Mulcahey, Accounts Manager, LC Sciences). 
 
3.1.11. mRNA microarrays 
The mRNA microarray analysis was performed by Genome Quebec (Montréal, 
Quebec, Canada; www. genomequebecplatforms.com). The sample used 250 ng of 
starting total RNA to hybridize 750 ng of biotin labeled cRNA on the RatRef-12 array. 
Amplification was performed using the Illumina TotalPrep RNA Amplification kit 
(Ambion, Austin, TX, USA). Illumina’s Gene Expression system uses a “direct 
hybridization” assay whereby biotin-labeled samples are hybridized individually to an 
array (Fig. 3.3). Following hybridization the transcripts were detected using Cy3 
conjugated streptavidin and scanned. The signal intensities generated provide an 
indication of the absolute abundance of transcripts within that population. The signal 
intensities generated from separate arrays can be compared as an indication of the 
differences between the two sample populations (Illumina, San Diego, CA, USA; 
www.illumina.com). 
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Figure 3.3. Direct Hybridization Assay Overview and Workflow. The Illumina Gene 
Expression protocol features a first- and second-strand reverse transcription step, 
followed by a single in vitro transcription (IVT) amplification that incorporates biotin-
labeled nucleotides. Subsequent steps include array hybridization, washing, blocking, and 
streptavadin-Cy3 staining. Fluorescence emission by Cy3 is quantitatively detected for 
downstream analysis (picture was taken from Illumina’s web-site). 
 
3.1.12. Semi-quantitative reverse transcription PCR (sqRT-PCR) 
The sqRT-PCR was performed by using Taq DNA Polymerase (Fermentas, 
Burlington, ON, Canada), specific primers and carried out on an Eppendorf Mastercycler 
PCR machine (Eppendorf, Hamburg, Germany). Primers were designed using Primer3 v. 
0.4.0 software (Rozen and Skaletsky, 2000) and synthesized by Integrated DNA 
Technologies (San Diego, CA, USA). Each reaction contained 1 μl of cDNA, 0.5 μl of 10 
μM forward and reverse primers, 2.5 μl of 10x Taq Buffer, 2.5 μl of 2 mM dNTPs, and 
0.25 μl of Taq DNA polymerase (5U/μl) in a total volume 25 μl. PCR conditions and 
primers’ sets are summarized in Table 3.1. PCR conditions where empirically determined 
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for each set of primers so that the concentration of PCR product was below saturation 
point. Agarose gel electrophoresis was carried out in 1x TAE buffer using a 1% agarose 
gel with ethidium bromide. The amplified product was visualized under UV light and 
quantified using ImageQuant 5.2 software (GE Healthcare, Piscataway, NJ, USA) and 
normalized to Gapdh gene expression. 
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Table 3.1. Primers and PCR conditions for sq-RT-PCR and cloning. 
Gene/ 
Object 
Primer Type 
of 
Primer 
Sequence Note 
List 
name 
Eps15 MS007 for 
AAATCTAGATAGTCCCAAAGAAAAGGA
TCCTGATATG L=464bp, from Rattus 
norvegicus gDNA or 
cDNA. For cloning into 
pGL3 with XbaI and FseI. 
Eps15 MS008 rev 
AAAGGCCGGCCGGCAAAGCTGTTTAAT
TAGGGTACTGC 
Nab1 MS013 for 
AAATCTAGACTGAGATTCTCCCCCTGCT
CTCTGG 
L=351bp, from Rattus 
norvegicus gDNA or 
cDNA. For cloning into 
pGL3 with XbaI and FseI. 
Nab1 MS014 rev 
AAAGGCCGGCCGGGATCCACGTCTATT
AGACTGCAAGG 
EPS15 
MS026 for 
GCCCCCCCTTCCAAAAGCAGTACCCTAA
T 
Initial denaturation - 98˚C 
for 30 sec, 30 cycles with 
initial denaturation 98˚C 
for 10 sec, annealing - 
62˚C for 30 sec, 
polymerization - 72˚C for 
30 sec, final extention -
72˚C for 3 min. 
MS027 rev P-AAAAGACACATTTGAAGTTCCCCC 
MS028 check 
GGGGAACTTCAAATGTGTCTTTTGCC 
NAB1 
MS044 for GATTGTCTTCAGCTCCCAGACCA Initial denaturation - 98˚C 
for 30 sec, 30 cycles with 
initial denaturation 98˚C 
for 10 sec, annealing - 
60˚C for 30 sec, 
polymerization - 72˚C for 
30 sec, final extention -
72˚C for 3 min. 
MS045 rev 
P-
ACACTGGTTATTAAGGCTTAATCTACGA
T 
MS046 check GTAGATTAAGCCTTAATAACCAGTGTG
AT 
ADIPOQ 
MS047 for ATGCTACTGTTGCAAGCGCTCC Initial denaturation - 95˚C 
for 3 min, 31 cycles with 
initial denaturation 95˚C 
for 30 sec, annealing - 
61.6˚C for 30 sec, 
polymerization - 72˚C for 
30 sec. 
MS048 rev 
TCAGTTGGTATCATGGTAGAGA 
Ephrinb3 
MS049 for ATGGGGGGCCCCCATTTTGGGCC Initial denaturation - 95˚C 
for 3 min, 32 cycles with 
initial denaturation 95˚C 
for 30 sec, annealing - 
62˚C for 30 sec, 
polymerization - 72˚C for 
30 sec. 
MS050 rev 
TCATACCTTGTAGTAGATGTTT 
GABRA4 
MS051 for ATGGTTTCTGTCCAGAAGGTAC Initial denaturation - 95˚C 
for 3 min, 29 cycles with 
initial denaturation 95˚C MS052 rev TTACATTAGACTTTCTGATTTC 
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for 30 sec, annealing - 
61˚C for 30 sec, 
polymerization - 72˚C for 
30 sec. 
PRLR 
MS053 for ATGCCATCTGCACTTGCTTTCG Initial denaturation - 95˚C 
for 3 min, 27 cycles with 
initial denaturation 95˚C 
for 30 sec, annealing - 
60.8˚C for 30 sec, 
polymerization - 72˚C for 
30 sec. 
MS054 rev 
TCAGTAGTCAAGTTCCCCTGCA 
GAPDH 
MS055 for CAAGGTCATCCATGACAACTTTG Initial denaturation - 95˚C 
for 3 min, 22 cycles with 
initial denaturation 95˚C 
for 30 sec, annealing - 
55˚C for 30 sec, 
polymerization - 72˚C for 
30 sec. 
MS056 rev 
GTCCACCACCCTGTTGCTGTAG 
pGL3 AG264 rev GGTTACAAATAAAGCAATAGCATCACA  
A2bp1 MS001 
A2bp1 
for AAAGGCCGGCCATGATAAAACCATTAA
ACAAACAAACAAAAAAC 
L=478bp, from Rattus 
norvegicus gDNA or 
cDNA. For cloning into 
pGL3 with FseI. 
A2bp1 MS002 
A2bp1 
rev 
AAAGGCCGGCCGGCCTCCCCTTTCACA
GAATAAAATAATATAG 
 
Creb5 MS003 
Creb5 
for AAATCTAGAAAGGCATCGGTCAAACCT
GGCC 
L=1745bp, from Mus 
musculus gDNA or cDNA. 
For cloning into pGL3 
with XbaI and FseI. 
Creb5 MS004 
Creb5 
rev 
AAAGGCCGGCCCTCTAAAATAGAATTT
TTTTTAAACTATAGTGAGCG 
 
MAP3K2 MS011 
MAP3
K2 for AAATCTAGACAGCCAGCGTCCTCCACCC
GCC 
L=156bp, from Rattus 
norvegicus gDNA or 
cDNA. For cloning into 
pGL3 with XbaI and FseI. 
MAP3K2 MS012 
MAP3
K2 rev 
AAAGGCCGGCCTTTAGTTTACTATTATT
ATTAAACAAATTTAACCAAG 
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3.1.13. miRNA target prediction 
miRNA targets for further analysis were predicted using basic seed-based 
algorithms (Lewis et al., 2005) from the Targetscan database (Whitehead Institute for 
Biomedical Research, Cambridge, MA, USA; www.targetscan.org). Predicted targets of a 
miRNA family were calculated as published earlier (Grimson et al., 2007) and sorted by 
total context score. The total context score was based on the following features: site-type 
contribution, 3' pairing contribution, local AU contribution, and position contribution 
(Grimson et al., 2007). 
  
3.1.14. Preparation of E. coli JM109 electrocompetent cells 
E. coli JM109 cells (Agilent Technology Inc./Stratagene, Santa Clara, CA, USA) 
were picked up from fresh LB/agar plates, inoculated into 20 ml of LB and grown 
overnight at 37˚C with shaking (200 rpm). The next day, 6 ml of overnight culture were 
inoculated into 300 ml of LB medium and grown at 37˚C with shaking (200 rpm) until 
OD600 = 0.6. Bacterial cells were chilled down on ice for 30 min and collected by 
centrifugation at +4˚C for 20 min, 4000 rpm. The bacterial pellet was washed 2 times in 
50 ml ice-cold sterile de-ionized water, one time in 10% ice-cold glycerol, and 
resuspended in 3 ml of 10% ice-cold glycerol. Cells were split into 80 μl aliquots and 
stored at -80˚C. 
 
3.1.15. Cloning 
The 3’- untranslated regions (UTR) of the Eps15 gene (NM_001009424) with a seed 
sequence for the miR-186 and Nab1 (NM_022856) genes with a seed sequence for miR-
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709 were amplified by PCR. They were then cloned into pGL3-Promoter vectors 
downstream of the Luciferase coding sequence. The PCR mix contained 10 μl of 5x GC 
buffer, 5 μl of 2 mM dNTPs, 1 μl of 10 μM forward and reverse primers (see Table 3.1), 
1 μl of cDNA, and 0.5 μl of Phusion® High-Fidelity DNA Polymerase (NEB, Ipswich, 
MA, USA) in a total volume of 50 μl. The PCR conditions were: initial denaturation – 30 
sec at 98˚C, 25 cycles with denaturation - 10 sec at 98˚C, annealing – 30 sec at 63˚C, 
polymerization – 30 sec at 72˚C, and final extension 10 min at 72˚C. 
 
The PCR fragments were analyzed by gel electrophoresis in 1% agarose/1x TAE 
buffer with ethidium bromide, and purified using a PCR purification kit (Qiagen, 
Valencia, CA, USA). Purified PCR fragments and pGL3-Promoter plasmid were digested 
with XbaI and FseI restriction endonucleases (NEB, Ipswich, MA, USA). After digestion 
they were purified using PCR purification kit (Qiagen, Valencia, CA, USA) and ligated 
overnight at 16˚C. The ligation reaction consisted of 2 μl of 10x ligation buffer, 300 ng of 
vector DNA, 400 ng of PCR fragments, and 2 μl of T4 DNA ligase (Fermentas, 
Burlington, ON, Canada) in a total volume of 20 μl. Ligation mixes were purified with 
phenol:chloroform, precipitated with ethanol, dissolved in ultra-pure water (NEB, 
Ipswich, MA, USA) and used for transformation of JM109 electrocompetent cells by 
electroporation (1600 V). After electroporation the transformed JM109 cells were plated 
on LB/agar plates supplemented with 50 μg/ml of kanamycin. Plates were incubated 
overnight at 37˚C. Resistant clones were screened by colony PCR using the DreamTaq 
DNA Polymerase (Fermentas, Burlington, ON, Canada) under the following conditions: 
initial denaturation - 95˚C for 5 min, 25 cycles with denaturation for 30 sec at 95˚C, 
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annealing - 55˚C for 30 sec, polymerization - 72˚C for 30 sec, and final elongation at 
72˚C for 1 min. PCR fragments were checked by gel electrophoresis in 1% agarose 
gel/1x TAE with ethidium bromide. Positive clones were transferred onto fresh 
LB/agar/kanamycin plates and stored at +4˚C. Resulted plasmids (pFN4 that is 
pGL3::Eps15-3’UTR and pFN7 - pGL3::Nab1-3’UTR) were used for generation of 
mismatch controls (without proper seed sequence region for miRNAs). 
 
3.1.16. Seed sequence mutagenesis 
To create mismatch controls the pFN4 plasmid was mutated with primers MS026 
and MS027, and pFN7 with primers MS044 and MS055 that carry mutated seed 
sequences (see Table 2). PCR fragments were generated with Phusion® High-Fidelity 
DNA Polymerase (see Cloning), extracted from the 1% agarose gel with QIAquick Gel 
Extraction Kit (Qiagen, Valencia, CA, USA) and self-ligated using T4 DNA ligase 
(Fermentas, Burlington, ON, Canada). Ligation reaction consisted of 2 μl of 10x ligation 
buffer, 10 μl of gel-purified PCR fragment DNA (10 ng/μl), and 2 μl of T4 DNA ligase in 
a total volume of 20 μl. The ligation mix was incubated overnight at 16˚C, 
phenol:chlorophorm was purified and used for transformation of electrocompetent E. coli 
JM109 cells. Mutated plasmids (pFN4mut and pFN7mut) were screened by colony PCR 
with corresponding primers: pFN4mut – MS028 and AG264 (see Fig.3.4, and Table 3.1), 
pFN47mut – MS046 and AG264 (Table 3.2). Original and mutated plasmids were 
confirmed by DNA sequencing. 
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3.1.17. Cell culture and Luciferase Reporter Assay 
Human embryonic kidney HEK-293 cells were maintained in DMEM (Invitrogen, 
Carlsbad, CA, USA), supplemented with 10% fetal bovine serum, penicillin (100U/ml) at 
37˚C in a 5% CO2 atmosphere. HEK293 cells were cotransfected in 24-well plates with 
the pGL3 vector (with Firefly luciferase) or tested construct, precursor miRNA, and 
control Renilla luciferase pRL-TK vector (Promega, Madison, WI, USA), using the 
Lipofectamine 2000 reagent according to the manufacturer’s protocol (Invitrogen, 
Carlsbad, CA, USA). Twenty-four hours after transfection, 1x Passive Lysis Buffer 
(Promega, Madison, WI, USA) was added to the transfected cells. Renilla and Firefly 
luciferase activities were measured using the dual-luciferase reporter assay system with 
Stop & Glow Reagent (Promega, Madison, WI, USA) according to the manufacturer’s 
instructions. A similar culture experiment was performed using another cell line, human 
breast cancer MCF-7 cells. Each cell line was tested in triplicate and reproduced twice in 
independent experiments. 
 
 
 
 
 
 
45 
 
A
 
B 
 
Figure 3.4. A: Schematic illustration of the seed sequence mutagenesis. The PCR 
fragment with a mutated seed sequence was obtained by inverse PCR with corresponding 
primers from the original pFN4 plasmid. The PCR fragment was self-ligated and used for 
transformation of JM109 electrocompetent cells. Recombinant clones were checked by 
colony PCR. The mutated seed sequence of the final construct was verified by 
sequencing. B: rno-miRNA-186 seed sequence (highlighted in red) was substituted with 
the mutated sequence (adenine was substituted by guanine, while thymine was substituted 
by guanine).  
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3.1.18. Analysis of genome-wide cytosine methylation  
Genomic DNA was extracted using Trizol reagent (Invitrogen, Carlsbad, CA, 
USA) according to manufacturer instructions. Cytosine-extension assay to detect 
sequence-specific alterations in DNA methylation was performed using a protocol by 
Pogribny et al. (1999). Briefly, 2 µg of genomic DNA was digested overnight with a 10-
fold excess of HpaII or MspI endonuclease according to manufacturer’s protocol (New 
England Biolabs, Beverly, MA, USA). A third DNA aliquot was incubated without 
restriction enzyme used as a background control. The single nucleotide extension reaction 
was carried out in a 25 µl reaction mixture containing 0.5 µg of DNA, 1x PCR buffer II, 
1.0 mM MgCl2, 0.25 units of AmpliTaq DNA polymerase (Perkin Elmer, Foster City, 
CA, USA), [
3
H]dCTP (57.4 Ci/mmol) (NEN, Boston, MA) and incubated at 56°C for 1 h, 
then placed on ice. Duplicate 10 µl aliquots from each reaction were applied on Whatman 
DE-81 ion-exchange filters and washed three times with Na-phosphate buffer (pH 7.0) at 
room temperature. The filters were dried and processed for scintillation counting. 
Background radiolabel incorporation was subtracted from enzyme-treated samples and 
the results were expressed as relative [
3
H]-dCTP incorporation/0.5µg DNA or as percent 
change from control samples (Pogribny et al., 1999). The data obtained from 3 
independent experimental groups with 2 measurements per group were expressed as a 
percentage of dpm/mg of DNA relative to background controls. Incorporation is directly 
dependent on the completeness of the DNA digestion with methylation-sensitive 
enzymes. Higher methylation is associated with a decrease in digestion rate and, thus, a 
lower incorporation of radioactively labeled cytosine ([
3
H]-dCTP). 
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3.1.19. Data analysis and statistics 
3.1.19.1. General statistics  
Statistical analysis was performed using Microsoft Excel Analysis ToolPak 
(Microsoft Corp., Redmond, WA, USA). All data are presented as the mean +/- standard 
deviation. Details of each type of analysis are provided in the following. 
 
3.1.19.2 miRNA microarray analysis 
The miRNA microarray data analysis was performed by LC Sciences (Houston, 
TX, USA). Data analysis included the determination of detectable signals, calculation of 
signal intensities, and, calculation of differential ratios. The data analysis process began 
with background subtraction, Cy3/Cy5 channel normalization, detectivity determination, 
and then p-value calculation for the determination of differential significance. Multiple 
sample analysis involved normalization, data adjustment, t-test/ANOVA analysis, and 
clustering. 
 
 Background Subtraction. The background was determined using a regression-
based background mapping method.  The regression was performed on the data points of 
5% to 25% of the lowest intensity, excluding blank spots. The raw data matrix was then 
subtracted from the background matrix. 
 
 Normalization. Normalization was carried out using a LOWESS (Locally-
weighted Regression) method on the background-subtracted data (Bolstad et al., 2003). 
The normalization allows removing system-related variations, such as sample amount 
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variations, different labeling dyes, and signal gain differences of scanners so that 
biological variations can be reliably revealed.   
 
 Detectivity Determination. Detectable transcripts met at least two conditions: 
signal intensity higher than 3 × (background standard deviation) and spot CV < 0.5. CV 
was calculated by (standard deviation)/(signal intensity). When repeating probes were 
present on an array, a transcript was listed as detectable only if the signals from at least 
50% of the repeating probes were above detection level. 
 
 P-Value Calculation. After the normalization, the p-values of the difference 
between Cy3 and Cy5 signals were calculated as following. Let StdCy3 and StdCy5 be 
the standard deviations Cy3 and Cy5 probe areas, respectively. Let Cy3 and Cy5 be the 
signal intensities (the values obtained after background subtraction and normalization) of 
the Cy3 and Cy5 probe areas. And let StdBkgCy3 and StdBkgCy5 be the standard 
deviations of background values of Cy3 and Cy5 channels. Let  
CStdCyStdCydferr
StdBkgCyStdBkgCyC


22
22
53
53
 
where C is a numeral number and dferr is a 1D array of size n.   
Let 
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and  
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If p(i) < 0.01, it was plotted as red spot in a log scatter plot.   
 
 Probe Standard Deviation. Probe standard deviation was obtained by multiplying 
Density (st.dev.) by the corresponding normalization correction factor as shown in the 
following formula:  
fStDev   
 
 P-value. In a dual sample assay, p-value was a measure of statistical significance 
of signal difference between two samples (Sample A and Sample B) on a detection probe.   
 Log2 Ratio. In a dual sample assay, a log2 ratio was a measure of signal difference 
between two samples on a detection probe. The log2 ratio was calculated according to the 
following formula: 







A
B
I
I
RLog 22 log
 
where, IA and IB are signal count (or intensity) of samples A and B, respectively. One can 
calculate the corresponding arithmetic ratio either by directly taking AB IIR /  or by 
indirectly converting log2 ratio using 
RLog
R 22 . 
 
 Data Adjustment. Data adjustment included data filtering, log2 transformation, 
and miRNAs centering and normalization. The data filtering removed miRNAs with 
(normalized) intensity values below a threshold value of 32 across all samples.  The log2 
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transformation converted intensity values into the log2 scale. Gene centering and 
normalization transform the log2 values using the mean and the standard deviation of 
individual genes across all samples using the following formula: 
Value = [(Value) – Mean (Gene)] / [Standard deviation (Gene)]. 
 
T-test. A t-test was performed between “control” and “stress” sample groups with 
each group containing at least two samples (Pan, 2002). T-values were calculated for 
each miRNA, and p-values were computed from the theoretical t-distribution. miRNAs 
with p-values below a critical p-value (p<0.01) were selected for cluster analysis. The 
clustering was performed using a hierarchical method and was performed with average 
linkage and Euclidean distance metric (Eisen et al., 1998).  
 
ANOVA (Analysis of Variance). The miRNAs with significant differences in 
means were picked out across three or more groups of samples, with each group 
containing at least two samples. In this analysis, p-values were computed from the F-
distribution. 
 
All data processes, except the clustering plot, were carried out using in-house 
developed computer programs. The clustering plot was generated using the TIGR MeV 
software (Multiple Experimental Viewer, location) from The Institute for Genomic 
Research (Information provided by Jason Mulcahey, Accounts Manager LC Sciences: 
www.lcsciences.com). 
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3.1.19.3. mRNA microarray analysis 
mRNA microarray analysis was performed using FlexArray 1.4.1 software 
(Blazejczyk et al., 2007). The data analysis was performed using the lumi Bioconductor 
package (Du et al., 2007), which was used for the pre-processing and normalizing of 
Illumina microarray data. Background correction was performed using Robust Multichip 
Average (RMA) background adjustment (Bolstad et al., 2003, Irizarry et al., 2003a, 
Irizarry et al., 2003b). Log2 data were normalized using Quantile normalization. A two-
sample student’s t-test was run to compare gene expression in different groups. Data were 
plotted using volcano plots of p-values. The list of genes 2-fold up- or down-regulated 
with a p-value of ≤ 0.05 was generated.  
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3.2. Results 
3.2.1. Body weight 
Body weight growth curves were not different between the control and the 
stressed groups (Fig. 3.5 and 3.6). 
 
Figure 3.5. Body weight growth curves. The average body weight gain dynamics of 
stressed animals after two weeks of stress is shown in blue. The average body weight 
gain dynamics of control animals after two weeks of the experiment is shown in red. 
 
The mean weight of animals in the stressed group (487.3±25.2 g) was 3.5% lower than 
that of the control group (504.5±29.2 g) (Fig. 3.6).  
53 
 
 
Figure 3.6. Body weight (means ± SD) after two weeks of stress (“after two weeks of 
stress”) and after two weeks of stress followed by two weeks of recovery (“post-stress”).  
 
3.2.2. Corticosterone and glucose levels 
Analysis of the concentration of plasma corticosterone in control animals and 
stressed animals showed significant differences (p<0.001) on the first day of stress (Fig. 
3.7). As expected, on the last day of stress and after recovery from stress, stressed 
animals had lower levels of corticosterone, which were similar to those in control 
animals. In contrast, there was no difference in glucose levels on the first day of stress 
between stressed and control animals (Fig. 3.8). The level of glucose was in general 
lower on the last day of stress as compared to the first day of stress in both control and 
stress groups.  
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Figure 3.7. Concentration of corticosterone (means ± SD; ng/ml) in plasma in control 
and stressed animals as measured on the first day of stress, last day of stress and after two 
weeks of recovery after stress (“post-stress”). Asterisks represent statistical significance 
(p<0.001). 
 
 
Figure 3.8. Plasma glucose level (means ± SD; ng/ml) in control and stressed animals on 
the first and last days of stress. 
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3.2.3. mRNA microarray analysis 
We analyzed the mRNA expression pattern in the following experimental groups: 
2 weeks of daily restraint stress (2WSTRESS, n=3), 2 weeks controls (2WCONTROL, 
n=3), 2 weeks of daily restraint stress + 2 weeks of recovery from stress (4WSTRESS, 
n=3), 4 weeks controls (4WCONTROL, n=3). Three RNA samples out of four per group 
were chosen for microarray analysis based on RNA quality and concentration. The 
RatRef-12 Expression BeadChip was used for genome-wide expression analysis that 
contains 21,910 probes selected primarily from the NCBI RefSeq database (Release 16).  
 
Microarray data analysis showed that after two weeks of restraint treatment 
(2WSTRESS) 39 genes changed significantly compared to respective controls 
(2WCONTROL): 36 were up-regulated, while three genes were down-regulated (see 
Table 3.2, Fig. 3.9). To exclude the possibility that these changes were due to changes in 
the control animals, we plotted 2WCONTROL vs. 4WCONTROL data, and found only 
three genes changed, all being up-regulated.  The changes observed upon comparison of 
RNA profile in the 2WSTRESS group of animals vs. 2WCONTROL of animals were 
nearly completely eliminated after two weeks of recovery after stress; comparison of the 
expression in the 4WSTRESS group with the expression in the 4WCONTOL group 
showed just 4 genes were altered and 2 of them were down-regulated. To verify the 
expression level of genes altered by stress after recovery from stress, we plotted 
4WSTRESS vs. 4WCONTOL with fold change < 1.3 and p-value < 0.1 and generated a 
list of the total number of 803 genes (data not shown). The comparison of expression of 7 
overlapping genes is shown in Table 3.3. The comparison of gene expression between the 
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4WSTRESS group and the 2WSTRESS group showed 12 genes were different, with 4 of 
them being down-regulated. None of the 12 genes in this comparison were from the 
above mentioned group of 39 genes. 
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Table 3.2. List of genes changed after two weeks of restraint treatment (2WSTRESS vs. 
2WCONTROL). 
Gene ID 
log2 (Fold 
change) T statistic P-value 
TC2N 1.155517 3.91912 0.01726049 
STRA6 1.320069 9.442759 0.000701395 
CLCA3_PREDICTED -1.30728 -4.380687 0.01186854 
NUDT7_PREDICTED 1.048149 2.844448 0.04665709 
LOC497720 2.586736 5.409068 0.005657964 
LOC689246 1.040238 2.907243 0.0437989 
RGD1563952_PREDICTED 1.062988 5.394357 0.005713646 
PI15_PREDICTED 1.395103 13.8289 0.000158493 
CITED1 1.338056 5.607811 0.004967005 
LOC500853 1.114951 5.316242 0.006020798 
GDF15 1.502859 3.510298 0.02466527 
CLDN3 1.517201 3.217527 0.03235646 
MGC114520 1.73252 3.273238 0.03069542 
ADIPOQ 1.044457 7.537308 0.001659459 
RGD1562658_PREDICTED 1.161843 3.426785 0.02661396 
LOC502201 1.0398 4.805946 0.008610718 
ITGB6 1.058206 6.962303 0.002236928 
OSMR 1.101128 8.684738 0.000967566 
FOLR1 1.91473 3.050852 0.03799655 
LOC361399 1.205812 4.283948 0.01280747 
LOC501293 1.445065 2.833147 0.0471942 
CLDN2_PREDICTED 2.523236 3.999483 0.01613703 
LOC497820 -1.115307 -3.295325 0.03006491 
PRLR 1.340845 3.885745 0.01775454 
LOC501363 1.120551 4.147749 0.01428635 
MSX1 1.636187 4.046863 0.01551584 
CDH3 1.007819 4.194682 0.01375455 
TCF21 1.14078 2.982395 0.04064249 
RGD1564074_PREDICTED 3.106724 4.402334 0.01166997 
LOC317599 1.810993 6.90011 0.002313331 
CAPN12_PREDICTED -1.002391 -3.37313 0.02796259 
CORIN 1.172354 3.127135 0.03528266 
LOC501482 1.026876 3.370437 0.02803238 
CRB3 1.132068 3.018464 0.0392224 
IQCG 1.041597 4.67263 0.009499686 
SLC26A7_PREDICTED 1.187831 3.096842 0.03633221 
LOC497864 1.275351 4.161759 0.01412505 
OTC 1.589388 2.998462 0.04000258 
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RGD1563000_PREDICTED 1.406052 4.786004 0.008737058 
 
 
 
 
Figure 3.9. mRNA microarray expression analysis. Genes with a 2-fold difference and a 
p-value of p<0.05 are shown. Genes that were changed are represented as dark-red 
diamonds, in top-left (down-regulated) and top-right (up-regulated) parts of each figure. 
2S_2C – groups of 2WSRESS vs. 2WCONTROL, 4C_2C – 4WCONTROL vs. 
2WCONROL , 4S_2S – 4WSTRESS vs. 2WSTRESS, 4S_2C – 4WSTRESS vs. 
2WCONTROL.    
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Table 3.3. Comparison of the gene expression levels. 
 
Target ID 
2WS vs. 2WC 4WS vs. 4WC 
log2(Fold change) P-value log2(Fold change) P-value 
CRB3 1.132 0.039 0.828 0.088 
NUDT7_PREDICTED 1.048 0.047 0.872 0.094 
ADIPOQ 1.044 0.002 0.579 0.006 
CDH3 1.008 0.014 0.682 0.086 
OSMR 1.101 0.001 0.883 0.088 
CORIN 1.172 0.035 0.746 0.058 
LOC501482 1.027 0.028 0.497 0.045 
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3.2.4. Semiquantitative RT-PCR 
To confirm changes in mRNA expression level we randomly chose two genes 
from the list of genes that changed after two weeks of stress (Table 3): prolactin receptor 
(Prlr) and adiponectin genes, C1Q and collagen domain containing gene (Adipoq). 
Gamma-aminobutyric acid (GABA) A receptor, alpha 4 gene (Gabra4) and ephrin B3 
gene (Efnb3) were used as controls. sq-RT-PCR was performed in duplicates using the 
same RNA samples that were used for microarray analysis. Sq-RT-PCR data analysis 
demonstrated similar levels of RNA expression in comparison to the microarray (more 
than 2-fold difference in expression level of Adipoq and Prlr, whereas no significant 
differences in expression of Gabra4 and Efnb3 were observed in the 2WSTRESS vs. 
2WCONTROL groups (Fig. 3.10, 3.11). Interestingly, our data showed significant age-
dependent changes in the expression level of Gabra4 and Efnb3 genes; 4WSTRESS and 
4WSTRESS samples showed higher expression than 2WSTRESS and 2WCONTROL 
(see Fig. 3.11). 
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A 
 
B 
 
Figure 3.10. sq-RT-PCR analysis.  A: prolactin receptor (Prlr) gene; B: Adipoq gene; 
Error bars represent standard deviation of the mean. Pictures below bars represent 
corresponding PCR fragments in duplicates for each animal. Data for 4 weeks are 
represented as an average for all three animals per group, while 2 weeks data show 
differences in expression for each animal per group.  Asterisks represent statistical 
significance  (*** - p<0.001; * - p<0.05). 
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C 
 
D 
 
Figure 3.11. sq-RT-PCR analysis.  C: ephrin B 3 receptor (Ef b3) gene; D: GABA (A) 
receptor 4 (Gabra4) gene. Error bars represent standard deviation of the mean. Data are 
represented as an average of three animals per group. Pictures below bars represent 
corresponding PCR fragments in duplicates for each animal for three animals per group.  
Asterisks represent statistical significance (** - p< 0.01; *** - p<0.001). 
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3.2.5. miRNA microarray analysis 
miRNA microarray analysis was performed using the µParaflo® Biochip, containing 832 
mature miRNA sequences. For analysis the following samples were used: 2 weeks of 
daily restraint stress (2WSTRESS, n=3) and 2 weeks controls (2WCONTROL, n=3). 
First, data with p-value p< 0.1 were analyzed. We found that nine miRNAs were changed 
in stressed animals in comparison to control (see Fig. 3.12). Three miRNAs changed 
significantly with a p-value p<0.05 in comparison to controls. Two miRNAs, miR-186 
and miR-381, were up-regulated, while miR-709 was down-regulated. For further 
analysis only miRNAs with the lowest p-value (p<0.01) were used, which included miR-
186 (fold change 0.43) and miR-709 (fold change -0.66). 
 
Figure 3.12: Analysis of miRNA expression in the rat cerebellum after two weeks of 
daily restraint treatment. The microarray heatmap demonstrates the log2 ratio of miRNA 
signal difference between control and stress samples. Up-regulated miRNAs are shown in 
red, while down-regulated miRNAs are shown in green. The first three columns on each 
figure represent the level of expression in control animals, while the three last columns 
represent the level of corresponding miRNA expression in stressed animals. 
 
3.2.6. Analysis of predicted miRNA targets 
There are no confirmed targets for miR-186 and miR-709 in the brain. 
Computational analysis of predicted targets for miR-186 revealed 365 putative miRNA 
targets, with a total of 398 conserved sites and 271 poorly conserved sites, with the score 
from -1.31 (most favorable) to 0.00. The context score for a specific site is the sum of the 
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contribution of four features: site-type contribution, 3' pairing contribution, local AU 
contribution, position contribution. The sum of the context scores for each miRNA was 
calculated, and the most favorable (i.e., lowest) is displayed. Predicted targets of a 
miRNA family are sorted by total context score, calculated as in Grimson et al. (2007). 
We examined the first 50 genes with the most favorable score (<-0.59). Among those we 
chose five targets which are important in the brain: Gabra4 (score: -1.31), Creb3 (-1.07), 
and Eps15 (-0.93), A2bp1 (-0.65), Map3k2 (-0.81). We were able to clone the wild and 
mutated seed sequence only of Eps15 into the plasmid used for Luciferase Reporter 
Assay, and thus we performed the analysis for Eps15 only (Fig. 3.13.). The 3’UTR of the 
Eps15 gene (NM_001009424) contains one binding site with a poorly conserved seed 
sequence for rno-miR-186 with one mismatch. The seed sequence is located 422-429 bp 
downstream of stop codon of Eps15 CDS. To confirm that Eps15 is indeed targeted by 
Mir-186 we carried out a luciferase reporter assay. The 3’UTR of the Eps15 gene was 
successfully cloned into the pGL3-promoter vector using the luciferase reporter gene. For 
the assay we were using MCF-7 and HEK-293 mammalian cell lines and the Dual-
Luciferase Assay system (Promega, USA), where the activities of firefly and Renilla 
luciferases were measured from each sample.  
 
Analysis of Luciferase Assay data showed that the luciferase activity was 
inhibited by miRNA-186 after co-transfection of mammalian cells with the construct 
carrying Eps-15 3’UTR in a dose-dependent manner (Fig. 3.14, 3.16). Co-transfection of 
mammalian cells with negative control (unrelated miRNA) revealed no changes in 
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Figure 3.13. Putative binding site of mir-186 in 3’UTR of its target Eps15. The seed 
sequence is represented in blue, while the mutated seed sequence is shown in red.  
 
 
luciferase activity. The same approach was used to assess the putative target of miRNA-
709 (3’UTR of Nab1 gene). Computational analysis of predicted targets revealed 331 
putative miRNA targets, with a total of 347 conserved sites and 193 poorly conserved, 
with the score from -0.81 (most favorable) to 0.00. We examined the first 50 genes that 
obtained the most favorable score (<-0.42). Among those we chose four targets which 
were reported of significant relevance to brain function: Creb5 (-0.56), Efnb3 (-0.6), 
Nav1 (-0.49), and Nab1 (-0.43). We were not able to clone wild and mutated seed 
sequences of Efnb3, Nav1 and the mutated seed sequence of Creb5. We continued further 
work with Nab1 only. The 3’UTR of Nab1 gene (NM_022856) contains one binding site 
with a poorly conserved seed sequence for rno-miR-709. The seed sequence is located 
84-91 bp downstream of stop codon of Nab1 CDS. Analysis of the Luciferase Assay data 
revealed no changes in expression of luciferase in the case of normal or mutated seed 
sequence (Fig. 3.16, 3.17).   
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Figure 3.14. Dose-dependent inhibition of Eps15 expression in the Luciferase Assay 
after transfection of HEK-293 cells with miR-186. Bars represent the normalized average 
of relative luciferase units. 
 
 
 
Figure 3.15. Dose-dependent action of Nab1 gene in the Luciferase Assay after 
transfection of MCF7 cells with miR-709. Bars represent the normalized average relative 
of luciferase units. 
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Figure 3.16. Luciferase Assay with pFN4 (3’UTR Nab1) and miR-186. The first bar 
demonstrates relative level of luciferase activity after transfection of MCF-7 cells with 
pFN4 only. Second bar: pFN4 + miR-186. Third bar: pFN4 mut + miR-186. Bars 
represent normalized average of relative luciferase units. Asterisks represent statistical 
significance (p<0.001) 
 
 
Figure 3.17. Luciferase Assay with pFN7 (3’UTR Nab1) and miR-709. The first bar 
demonstrates relative level of luciferase activity after transfection of MCF-7 cells with 
pFN7 only. Second bar: pFN7 + miR-709. Third bar: pFN7 mut + miR-709. Bars 
represent the normalized average of relative luciferase units. 
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3.2.8. Cloning 
In order to confirm putative miRNA targets we needed to clone 3’UTRs of 
miRNA predicted targets. The choice of 3’UTRs is explained above in Analysis of 
predicted miRNA targets. We have successfully cloned 3’UTRs of the following genes: 
Eps15, Nab1, A2bp1, Creb5, Map3k2. 3’UTR of Eps15 was cloned under GFP and 
Luciferase reporter genes.  3’UTRs of Map3k2, A2bp1, and Creb5 were cloned under the 
GFP reporter gene, while 3’UTR of Nab1 was cloned under the Luciferase reporter gene 
(see table 3.4). For colony PCR results see supplemental materials. 
 
Table 3.4. Cloned 3’UTRs 
Name 3’UTR Background plasmid miRNA 
pFN4 Eps15 Luciferase reporter miR-186 
pFN7 Nab1 Luciferase reporter miR-709 
pGK4 Eps15 GFP reporter miR-186 
pGK6 Map3k2 GFP reporter miR-186 
pGK1 A2bp1 GFP reporter miR-186 
pGK2 Creb5 GFP reporter miR-709 
 
 
3.2.9. Analysis of genome-wide cytosine methylation  
Analysis of the level of genome-wide cytosine methylation was done to asses if 
observed differences in the gene expression patterns after restraint treatment were caused 
by differences in the genome-wide methylation. Analysis revealed no changes in the level 
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of genome-wide cytosine methylation between stress and control groups of animals (Fig. 
3.18).  
 
Figure 3.18. Genome-wide cytosine methylation. The “Y” axis shows the percentage 
(mean ±SD) level of genome-wide cytosine methylation in cerebellum of animals after 
two weeks (“2 weeks”) of stress and two weeks of recovery after two weeks of stress (“4 
weeks”).
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3.3. Discussion  
The purpose of this research was to quantify the extent of epigenetic adaptation to 
a chronic mild stressor in the cerebellum using a rat model. mRNA and miRNA 
expression profiles were assayed in animals exposed to two weeks of daily restraint stress 
and two weeks after cessation of stress in comparison to no-stress controls. The results 
revealed that chronic stress caused changes in gene and miRNA expression in the 
cerebellum. Furthermore, we verified one putative target for one of the changed miRNAs 
and expression of four randomly selected genes. 
 
3.3.1. Physiological and behavioural changes 
Chronic restraint stress in the present study caused elevated CORT levels on the 
first day of stress, which is in line with previously reported data (Magarinos and 
McEwen, 1995b, Faraday, 2002, Kirkland et al., 2008). Furthermore, we observed that 
animals show habituation to stress by 14 days of daily restraint treatment. The lack of 
chronic elevation is in accordance with the notion that rats may habituate to stress across 
subsequent exposures. For example, Magarinos and colleagues reported that daily chronic 
restraint stress caused a significant habituation by day 21 in the corticosterone response 
(Magarinos and McEwen, 1995a).  
 
Our experiment also revealed that there were no differences in body weight gain 
after two weeks of stress in the experimental group. There also were no differences 
between stress and control animals after two weeks of recovery after stress. These results 
are consistent with previous results showing an absence of body weight gain after two 
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weeks of restraint treatment (Jadavji and Metz, 2008). However, sex differences were 
observed during the post-stress period in that males gained significantly more weight than 
females. Moreover, Jadavji and Metz (2008) showed corresponding behavioural changes 
in motor performance. Interestingly, males did not recover from stress-induced 
impairment during a post-stress recovery period of two weeks. We hypothesized that the 
long-lasting disturbances in motor performance in male rats might be caused by 
epigenetically regulated changes in gene expression in the cerebellum. The results in the 
present study revealed that chronic stress indeed causes changes in the gene expression 
pattern in the cerebellum. However, the role of the genes which changed after restraint 
treatment in the motor performance still needs to be investigated. For further studies we 
can use a few approaches. To begin with, we can treat rats with artificial miRNAs that 
will target transcripts of changed genes and asses changes in motor performance. As an 
alternative, we can treat rats with antibodies against target proteins and monitor 
differences in rat behaviour. As a long-term goal, we can try to generate knocked-out or 
knocked-down rats/mice with mutated genes important for motor functions and/or 
behaviour. 
 
3.3.2. Chronic restraint stress causes changes in mRNA expression in cerebellum 
Our results revealed that chronic restraint stress causes changes in gene 
expression in the cerebellum. After two weeks of restraint treatment we observed up-
regulation in 36 genes, while three genes were down-regulated: Clca3 predicted, 
LOC497820, Capn12 predicted. Among the total number of changed genes 23 belong to 
the category of predicted genes. For further analysis we considered only the remaining 16 
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genes with known function. For a summary of diseases associated with the altered genes 
see supplemental materials (Table S8).  Interestingly, 14 out of 16 genes were reported to 
be involved in different types of cancer (Fig. 3.19). 
The following will discuss some of the most prominent mRNA and miRNA 
changes in detail. 
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B 
 
Figure 3.19. Gene classification. A: Total number of genes changed after two weeks of 
stress. B: Genes with confirmed expression.  
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3.3.2.1. Adipoq 
Our results showed a two-fold difference in expression of Adipoq. Adipoq is a 
gene which encodes adiponectin protein, which circulates in the plasma and is important 
in glucose and lipid metabolism (Qi et al., 2004). It is expressed exclusively in white 
adipose tissue and is abundantly present in human plasma (Liu et al., 2007). Low levels 
of adiponectin are associated with diabetes and there is a negative correlation between 
adiponectin and glucose levels in plasma (Tsao et al., 2002, Qi et al., 2004, Wang et al., 
2010). It was reported that adiponectin activates three downstream pathways: AMPK 
phosphorylation, PPAR-α and p38-Mitogen-Activated Protein Kinase (MAPK) in liver 
and skeletal muscle, where it has the highest expression (Kadowaki and Yamauchi, 2005, 
Yoon et al., 2006). 
 
The function of adiponectin in the brain is poorly understood, however, 
adiponectin receptors have been detected in the brain (Yamauchi et al., 2003). In 
particular, Yamauchi et al. (2003) demonstrated that the adiponectin receptors AdipoR1 
and AdipoR2 are expressed in the hypothalamus to mediate glucose uptake by 
adiponectin (Yamauchi et al., 2003). Adiponectin receptors are expressed ubiquitously 
throughout the body (Kubota et al., 2007). Adiponectin was reported to mediate increased 
AMP kinase activity in the hypothalamus and stimulate food consumption (Yamauchi et 
al., 2003, Kubota et al., 2007). It has been shown that in leptin-deficient obese mice, 
adiponectin acts in the brain to reduce plasma glucose by 71%, insulin by 52%, 
triglycerides by 17% and total cholesterol by 29% (Qi et al., 2004, Hoyda, 2009). 
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Up to date there exists controversy regarding adiponectin expression in the brain. 
In the rat model experiments, the level of adiponectin was increased in the cerebrospinal 
fluid (CSF), but not in the plasma after intravenous injection (Qi et al., 2004), suggesting 
that the brain might be an important target for this hormone. According to Spranger et al. 
(2006), adiponectin is not expressed in the CNS (Spranger et al., 2006). In their 
experiments they failed to detect adiponectin in human CSF samples and also did not find 
evidence of adiponectin crossing the blood brain barrier (BBB) (Spranger et al., 2006). 
However, the authors showed that brain endothelial cells express adiponectin receptors 
(Spranger et al., 2006). Nevertheless, several studies reported that adiponectin exists in 
human CSF at a 0.1% of serum concentration (Kos et al., 2007, Kusminski et al., 2007). 
 
Here we provided the first evidence that Adipoq mRNA is expressed in the 
nervous system. It is very unlikely that translation-capable Adipoq mRNA will reach the 
brain with plasma without being degraded. Moreover, it is not known if the molecule is 
actually able to cross the BBB. Spranger et al. (2006) reported that adiponectin mRNA 
was not present in brain microvessels harvested from mice (Spranger et al., 2006). 
Therefore, our data strongly suggest that Adipoq mRNA detected in cerebellum should be 
accounted for by local expression. 
 
Aside from direct effects via central receptors, adiponectin may also act through 
cell adhesion molecules. Interestingly, it has been proposed that adiponectin binds to the 
T-Cadherin molecule (Hug et al., 2004). T-Cadherin can actively bind to some forms of 
adiponectin, suggesting its role as a possible part of a more complex signaling structure 
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(Hug et al., 2004, Hoyda, 2009). T-Cadherin belongs to a large family of proteins 
involved in calcium mediated cell–to-cell interactions and extracellular signaling (Hug et 
al., 2004). The function of T-Cadherin in the adiponectin system remains to be elucidated 
(Hoyda, 2009). Intriguingly, in our experiments we have observed that increased 
expression of the Adipoq gene occurred simultaneously with the up-regulation of the 
predicted Cdh3 gene in the cerebellum. Cdh3 is a P-Cadherin gene which is 
overexpressed in the majority of pancreatic cancer, but not in healthy cells (Imai et al., 
2008). Imai et al. (2008) proposed that Cdh3 is a novel tumor-associated antigen, which 
can be used in cancer immunotherapy (Imai et al., 2008). Taking into consideration that 
experiments in mice suggest a role of AdipoR2 in pancreatic islet cell maintenance (Liu et 
al., 2007, Hoyda, 2009), there might be some connection between Cdh3 and Adipoq 
functions in the process of developing pancreatic cancer. 
 
Among other functions adiponectin is also implicated in regulation of blood 
pressure. Tanida et al. (2007) reported that adiponectin decreases blood pressure and 
sympathetic nerve activity in rats in a dose-dependent manner (Tanida et al., 2007).  
 
Interestingly, it was recently shown that adiponectin might be implicated in the 
pathophysiology of autism (Fujita-Shimizu et al., 2010). Mori and colleagues showed that 
serum levels of adiponectin in subjects with autism were significantly lower than those of 
normal controls (Fujita-Shimizu et al., 2010). Thus, we can conclude that functions of 
adiponectin are diverse and its specific role in the brain remains to be further 
investigated. 
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3.3.2.2. Prolactin receptor (PRLR) 
The prolactin receptors are abundant in most tissues, with the highest expression 
in the liver, mammary glands, adrenal glands and hypothalamus (Brandebourg et al., 
2007). Our results demonstrated that chronic restraint stress resulted in a two-fold 
increase in expression of prolactin receptor mRNA in the cerebellum. These findings are 
in consistency with previous results reporting that restraint stress in water causes up-
regulation of the PRLR in the brain, specifically in the choroid plexus (Fujikawa et al., 
1995).  
 
Prolactin (PRL) is a hormone produced by the pituitary, which is closely 
associated with the stress response (Fujikawa et al., 2004, Brandebourg et al., 2007). 
Torner et al. (2001) hypothesized that prolactin might play a role in emotional responses 
and HPA axis reactivity (Torner et al., 2001). Evidence from their experiments in a rat 
model suggests that prolactin is a neuromodulator of behavioural and neuroendocrine 
stress-responses, since it has central actions as an endogenous anxiolytic and anti-stress 
agent (Torner et al., 2001). PRL functions were also implicated in reproduction, 
development, metabolic and immune processes, brain function and behaviour 
(Brandebourg et al., 2007). The results by Fujikawa et al. (1995) suggest that in response 
to restraint stress PRL levels increase and move from the circulation to the CSF, where it 
acts on the central nervous system (Fujikawa et al., 1995). These authors also 
demonstrated that circulating PRL causes prolactin receptor expression in the 
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hypothalamus, suggesting a preventive role against stress-induced hypocalcemia and 
ulcerogenesis (Fujikawa et al., 1995).  
 
Interestingly, Ben-Jonathan and colleagues (2003) discovered that PRL and PRLR 
are produced in human adipose tissue (Zinger et al., 2003). Since examination of adipose 
tissue from rodents and murine pre-adipocyte cell lines failed to detect PRL expression 
and release, the Ben-Jonathan group concluded that expression of PRL in tissues other 
than the pituitary is unique to humans and primates (Brandebourg et al., 2007). 
 
3.3.2.3. EphrinB3 and GabaA4 receptors 
EphrinB3 Receptors. The ephrin receptors represent a large family of receptor 
protein tyrosine kinases, which play a crucial role in neuronal survival, axonal 
pathfinding and establishing neuron-target connections during embryonic development 
(Willson et al., 2006). The expression of ephrin receptors in the CNS is higher in 
embryos than in adults and differs depending on the type of receptors (Carpenter et al., 
1995, O'Leary and Wilkinson, 1999). For instance, an abundance of EphrinA receptors 
were shown to be expressed in the adult CNS, while expression of only a few EphrinB 
receptors was found in the adult brain (Willson et al., 2006). There is a controversy about 
the expression of mRNA and protein of EphrinB3 receptor in the adult brain, although 
Ephrinb3 mRNA expression was reported in several adult mouse tissues, including whole 
brain and adult rat spinal cord (Ciossek et al., 1995, Miranda et al., 1999, Willson et al., 
2006). The results of Willson et al. (2006) demonstrated that EphrinB3 receptors (both 
mRNA and proteins) are abundantly expressed throughout the adult rat brain, with the 
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most prominent expression in the cerebellum, suggesting that its functional role expands 
beyond embryonic development (Willson et al., 2006). EphrinB3 receptors and their 
ligands might play a role in maintaining formed axonal connections and synapses, as well 
as regulate synaptic plasticity in the mature nervous system  (Willson et al., 2006).  
 
Interestingly, our results showed up-regulation of ephrinB3 mRNA expression in 
two week groups (2WSTRESS + 2WCONTROL) in comparison to our four week groups 
(4WSTRESS + 4WCONTROL) (Fig. 3.11.C), while there were no changes in expression 
after stress treatment. We found up-regulation of Efnb3 mRNA in two weeks control 
animals as compared to four weeks animals. We speculate that there is an age-dependent 
effect on its expression. Similarly to EphrinB3, the expression of GABA (A) receptor 4 
also changed in two and four week groups of control animals (Fig. 3.11.D). 
 
Gabra4 receptors. γ-Aminobutyric acid (GABA) receptors are signaling proteins 
that represent the major inhibitory neurotransmitter receptors in the central nervous 
system (Sieghart et al., 1999). It was reported that the GABA (A) receptor 4 gene 
(Gabra4) could contribute to autism susceptibility in humans (Ma et al., 2005, Collins et 
al., 2006). Chugani et al. (2001) have observed age-related changes in the distribution of 
the GABA (A) receptors in the brain of epileptic children (Chugani et al., 2001). Their 
results demonstrated the highest expression of GABA receptors in the brain at the 
youngest age measured (2 years), which decreased exponentially with age (Chugani et 
al., 2001). 
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Age-dependent differences were also reported for the distribution across the brain 
of various GABA (A) receptor subunits in rats (Laurie et al., 1992, Poulter et al., 1992, 
Davis et al., 2000). Studies by Laurie et al. (1992) examined the embryonic and postnatal 
expression of 13 GABA (A) receptor subunit genes in the rat CNS, showing that each 
subunit exhibits a unique regional and temporal developmental expression profile (Laurie 
et al., 1992). For instance, the expression of GABA (A) subunit 4 had its peak at 
postnatal day 12, whereas subunit 1 and 6 mRNA increased with age, in contrast to 
subunits 2 and 3 which were down-regulated in cerebellum (Laurie et al., 1992). 
 
3.3.3. Chronic restraint stress causes changes in miRNA expression in the 
cerebellum 
 There were also changes in miRNA molecules whose functions are not well 
known yet. In particular, miR-186 and miR-709, which changed significantly in response 
to stress, do not belong to those which are abundantly expressed in the brain, and 
particularly in the cerebellum. There is a lack of previous data on the expression of these 
miRNAs while their functions and verified targets are still unknown. However, miR-186 
was reported to be expressed by postnatal oligodendrocyte lineage cells (Lau et al., 
2008). Our experiment revealed that miR-186 can target Eps15 in mammalian cells. 
Nowadays there is no agreement on the specific rules of target recognition by miRNA. 
Some authors suggest that it requires a perfect match between the seed sequence and the 
miRNA binding site (Rodriguez-Lebron and Paulson, 2006), while others speculate that a 
nearly perfect match in the seed sequence is enough for target recognition (Ioshikhes et 
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al., 2007). We have found that for the efficient regulation of a target gene (Eps15) the 
seed sequence miR-186 can have one mismatch. 
 
3.3.4. Epidermal growth factor receptor pathway substrate 15  
Epidermal growth factor (EGF) receptor pathway substrate 15 gene (Eps15) was 
first identified as an endogenous substrate for the EGF1 receptor kinase (Fazioli et al., 
1993). Eps15 is believed to have an important role in vesicular traffic, but its exact 
function is still unknown (Cupers et al., 1997). There is some evidence that Eps15 may 
play a role in the clathrin-mediated endocytosis of synaptic vesicle membranes (Chen et 
al., 1998). It was shown that Eps15 is concentrated in the presynaptic nerve terminals in 
rat brain, suggesting a role in the molecular rearrangement of the clathrin coats (Chen et 
al., 1998). Some data also suggest that Eps15 might be important for mitogenic signaling 
(Salcini et al., 1999). There are some human pathologies associated with Eps15 such as 
neuroblastoma and acute lymphoblastic and myeloid leukemias, since Eps15 is located on 
chromosome 1p31-p32, a region with several non-random chromosomal abnormalities 
(Salcini et al., 1999). 
 
3.3.5. Analysis of genome-wide cytosine methylation  
Analysis of the level of genome-wide cytosine methylation revealed no changes 
between stress and control groups of animals. Though, the level of methylated cytosines 
appeared to be in the range of 50-80%, which is consistent with the reported normal 
methylation level for mammals (Razin and Riggs, 1980). Methylation data are not 
conclusive because they represent mean numbers for two animals per group. Two other 
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data points per group were excluded from the analysis because of a broken scintillation 
counter.  
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3.4. Conclusions and Future Perspectives 
In conclusion, our results show that chronic restraint stress changes mRNA and 
miRNA expression in the cerebellum. The expression of 39 genes was changed 
significantly after two weeks of restraint treatment. We confirmed the expression of four 
randomly selected genes. We also demonstrated that stress changes the miRNA 
expression pattern in the cerebellum. In particular, Eps15 was confirmed as a target for 
one of the significantly changed miRNAs, miR-186.  
 
The present study was focused mainly on the miRNA component of epigenetic 
regulation of the stress response in the cerebellum. It would be interesting to assess other 
epigenetic changes, such as DNA methylation and histone modifications in the 
cerebellum as well as in other brain areas. Our results showed that stress causes alteration 
in the expression of prolactin receptor in male rats. Since prolactin plays an important 
role in lactation, it would be interesting to assess sex differences in the stress response. 
 
It would be interesting to investigate the role of the genes which changed after 
restraint treatment in the motor performance. We can treat rats with artificial miRNAs 
that will target transcripts of changed genes and asses changes in motor performance. As 
an alternative, we can treat rats with antibodies against target proteins and monitor 
differences in rat's behaviour. As a long-term goal, we can try to generate knocked-out or 
knocked-down rats/mice with mutated genes important for motor functions and/or 
behaviour. 
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Supplemental Materials 
 
 
Figure S1. Gel electrophoresis of DNA fragments after colony PCR for pFN4. Each PCR 
fragment represents one positive recombinant clone.   
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Figure S2. Gel electrophoresis of DNA fragments after colony PCR for pFN7. Each PCR 
fragment represents one positive recombinant clone.   
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Figure S3. Gel electrophoresis of DNA fragments after colony PCR for pGK4. Each 
PCR fragment represents one positive recombinant clone 
 
Figure S4. Gel electrophoresis of DNA fragments after colony PCR for pGK1. Each 
PCR fragment represents one positive recombinant clone 
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Figure S5. Gel electrophoresis of DNA fragments after colony PCR for pGK2. Each 
PCR fragment represents one positive recombinant clone 
 
Figure S6. Gel electrophoresis of DNA fragments after colony PCR for pGK6. Each 
PCR fragment represents one positive recombinant clone 
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Statistics 
 
 
Figure S7. Analysis of frequency distribution of corticosterone in 
plasma. Some data (represented in red, orange and green) show 
deviation from normal distribution.  
 
 
Figure S8. Analysis of frequency distribution of glucose in plasma. 
Some data points (represented in green and in orange) show deviation 
from normal distribution.  
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Luciferase assay 
 
 
Figure S9. Analysis of frequency distribution of Luciferase activity 
measurements. Data represented in blue show minor deviation from 
normal distribution. 
 
 
Table S1.  Statistics for plasma corticosterone 
 
F-Test Two-Sample for Variances  
   
  contol stress 
Mean 122.1225 311.3054 
Variance 2150.31 5764.027 
Observations 6 6 
df 5 5 
F 0.373057  
P(F<=f) one-tail 0.151528  
F Critical one-tail 0.198007   
   
   
t-Test: Two-Sample Assuming Equal Variances 
   
  contol stress 
Mean 122.1225 311.3054 
Variance 2150.31 5764.027 
Observations 6 6 
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Pooled Variance 3957.168  
Hypothesized Mean Difference 0  
df 10  
t Stat -5.20895  
P(T<=t) one-tail 0.000198  
t Critical one-tail 1.812461  
P(T<=t) two-tail 0.000396  
t Critical two-tail 2.228139   
 
 
 
Table S2. Statistics for Prlr (2 Weeks) 
 
F-Test Two-Sample for Variances   
   
  control stress 
Mean 453.4189601 1610.599 
Variance 130331.8563 27983.2 
Observations 6 6 
df 5 5 
F 4.657503549  
P(F<=f) one-tail 0.058319633  
F Critical one-tail 5.050329058   
   
t-Test: Two-Sample Assuming Equal Variances  
   
  control stress 
Mean 453.4189601 1610.599 
Variance 130331.8563 27983.2 
Observations 6 6 
Pooled Variance 79157.52846  
Hypothesized Mean Difference 0  
df 10  
t Stat -7.123859898  
P(T<=t) one-tail 1.60146E-05  
t Critical one-tail 1.812461102  
P(T<=t) two-tail 3.20291E-05  
t Critical two-tail 2.228138842   
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Table S3. Statistics for Adipoq (2 weeks) 
 
F-Test Two-Sample for Variances   
   
  control stress 
Mean 1172.044393 2802.164 
Variance 1340189.63 1611768 
Observations 6 6 
df 5 5 
F 0.831502624  
P(F<=f) one-tail 0.422238436  
F Critical one-tail 0.1980069   
   
t-Test: Two-Sample Assuming Equal Variances  
   
  control stress 
Mean 1172.044393 2802.164 
Variance 1340189.63 1611768 
Observations 6 6 
Pooled Variance 1475979  
Hypothesized Mean Difference 0  
df 10  
t Stat 
-
2.324020098  
P(T<=t) one-tail 0.021240423  
t Critical one-tail 1.812461102  
P(T<=t) two-tail 0.042480846  
t Critical two-tail 2.228138842   
 
 
 
Table S4. Statistics for Efnb3 (control) 
 
F-Test Two-Sample for Variances  
   
  2 weeks 4 weeks 
Mean 445.58 1396.573 
Variance 54236.02 279612.1 
Observations 6 6 
df 5 5 
F 0.193969  
P(F<=f) one-tail 0.048055  
F Critical one-tail 0.198007   
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t-Test: Two-Sample Assuming Unequal Variances 
   
  2 weeks 4 weeks 
Mean 445.58 1396.573 
Variance 54236.02 279612.1 
Observations 6 6 
Hypothesized Mean Difference 0  
df 7  
t Stat -4.03161  
P(T<=t) one-tail 0.002493  
t Critical one-tail 1.894579  
P(T<=t) two-tail 0.004986  
t Critical two-tail 2.364624   
 
 
 
Table S5. Statistics for Gabra4 (control) 
  
F-Test Two-Sample for Variances  
   
  2 weeks 4 weeks 
Mean 2315.441903 5961.082 
Variance 307081.2376 319452.8 
Observations 6 6 
df 5 5 
F 0.961272659  
P(F<=f) one-tail 0.483242318  
F Critical one-tail 0.1980069   
   
t-Test: Two-Sample Assuming Equal Variances  
   
  2 weeks 4 weeks 
Mean 2315.441903 5961.082 
Variance 307081.2376 319452.8 
Observations 6 6 
Pooled Variance 313267.0161  
Hypothesized Mean Difference 0  
df 10  
t Stat 
-
11.28176569  
P(T<=t) one-tail 2.60423E-07  
t Critical one-tail 1.812461102  
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P(T<=t) two-tail 5.20847E-07  
t Critical two-tail 2.228138842   
 
 
 
 
Table S6. Statistics for Gabra4 (stress) 
 
F-Test Two-Sample for Variances  
   
  2 weeks 4 weeks 
Mean 2315.441903 5961.082 
Variance 307081.2376 319452.8 
Observations 6 6 
df 5 5 
F 0.961272659  
P(F<=f) one-tail 0.483242318  
F Critical one-tail 0.1980069   
   
t-Test: Two-Sample Assuming Equal Variances  
   
  2 weeks 4 weeks 
Mean 2315.441903 5961.082 
Variance 307081.2376 319452.8 
Observations 6 6 
Pooled Variance 313267.0161  
Hypothesized Mean Difference 0  
df 10  
t Stat 
-
11.28176569  
P(T<=t) one-tail 2.60423E-07  
t Critical one-tail 1.812461102  
P(T<=t) two-tail 5.20847E-07  
t Critical two-tail 2.228138842   
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Table S7. Statistics for Luciferase assay 
F-Test Two-Sample for Variances   
   
  wild + miRNA 
no 
miRNA 
Mean 4.618685143 1.554974 
Variance 3.837194944 0.151151 
Observations 15 10 
df 14 9 
F 25.38652116  
P(F<=f) one-tail 1.63368E-05  
F Critical one-tail 3.025472724   
   
t-Test: Two-Sample Assuming Unequal Variances  
   
  wild + miRNA 
no 
miRNA 
Mean 4.618685143 1.554974 
Variance 3.837194944 0.151151 
Observations 15 10 
Hypothesized Mean Difference 0  
df 16  
t Stat 5.886006718  
P(T<=t) one-tail 1.14976E-05  
t Critical one-tail 1.745883669  
P(T<=t) two-tail 2.29953E-05  
t Critical two-tail 2.119905285   
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Table S8. Disease relationships for genes that changed after two weeks of restraint 
treatment (2WS vs. 2WC) (Taken from The GeneCards Human Gene Database, 
Weizmann Institute of Science, with minor modifications; www.genecards.org). 
Disease1 Articles2 PubMed IDs for Articles with Shared Sentences (# sentences)3 
STRA6 
matthew-wood syndrome 3 18316031 (2), 19760653 (1) 
anophthalmia 3 19839040 (2), 19112531 (1) 
pagod syndrome 1 19760653 (1) 
microphthalmia 1 19112531 (1) 
malformation 2 19112531 (1), 18316031 (1) 
pda 1 19839040 (1) 
TC2N 
abscess; liver 1 19688750 (1) 
dystrophy (muscular) 1 17512949 (1) 
pigmentosa; retinitis 1 18387594 (1) 
mental retardation 1 18387594 (1) 
abscess 1 19688750 (1) 
shock 1 17407182 (1) 
MSX1 
hypodontia 37 10861665 (4), 18788550 (3), 16682758 (3), 16498076 (3)  
agenesis 31 17559452 (4), 17973693 (3), 17651126 (3), 8696335 (2)  
cleft palate 23 16868654 (4), 12163415 (4), 9870533 (2), 9830770 (2)  
cleft lip 19 15379328 (4), 9003904 (2), 17557248 (2), 16868654 (2) 
msx1 gene mutation 3 18788550 (1), 17559452 (1), 16687911 (1) 
syndrome, wolf-hirschhorn 6 1969845 (3), 14630905 (2), 1685989 (1) 
orofacial cleft, nonsyndromic 3 18932005 (3) 
ellis-van creveld 3 8882877 (3) 
skin; appendage 3 7537773 (3) 
craniofacial abnormalities 3 14654219 (1), 12701100 (1), 12163415 (1) 
GDF15 
fibrodysplasia ossificans 
progressiva 45 17967130 (6), 19255227 (5), 17516498 (5), 19896889 (3)  
fusion; spine 18 15537446 (3), 15897826 (2), 11716009 (2), 19917933 (1) 
heterotopic ossification 26 3263906 (5), 19255227 (2), 19043134 (2), 17967130 (2) 
                                                          
1
 Disease - The name of the disease related to GeneCards gene. 
2
 Articles - The number of articles in which both the gene's symbol or description and the 
disease appear. 
3
 PubMed IDs for Articles with Shared Sentences (# sentences) - PubMed IDs of articles 
in which both the gene symbol and the disease appear in the same sentence, sorted by the 
number of sentences (shown in parentheses in the column) in which they both appear.  
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familial pulmonary arterial 
hypertension 9 20204735 (3), 17989347 (2), 19153267 (1), 18436795 (1)  
osteosarcoma 52 8519127 (5), 10939432 (5), 7951046 (4), 11169148 (4)  
juvenile polyposis 10 19318548 (2), 15235019 (2), 19622104 (1), 18756288 (1)  
fracture non-union 10 19597895 (2), 17669279 (2), 12429748 (2), 8589196 (1)  
gastric hamartoma 4 19318548 (4) 
ineffective erythropoiesis 8 20182355 (4), 20001631 (1), 19400694 (1), 19036111 (1)  
primary pulmonary hypertension 13 12740218 (4), 15192043 (3), 19324947 (1), 16361357 (1)  
FOLR1 
ovarian cancer 126 19617914 (7), 19454358 (6), 9426700 (5), 19189636 (5)  
deficiency; folate 22 15641086 (5), 9301457 (2), 18355335 (2), 8126512 (1)  
epidermoid carcinoma, 
nasopharyngeal 5 2605182 (1), 2430957 (1), 16478640 (1), 12757377 (1)  
neural tube defect 16 18804286 (3), 11102926 (2), 10234517 (2), 9545095 (1)  
ovarian tumor 15 18357444 (3), 9099956 (2), 19585555 (2), 18222534 (2)  
oral cancer 11 20023317 (1), 19435095 (1), 19088031 (1), 16564654 (1)  
mesothelioma 10 12019370 (4), 11174727 (3), 20051956 (2), 19839924 (1) 
leukemia l1210 5 9037255 (1), 8765468 (1), 7488246 (1), 2353941 (1)  
human mammary carcinoma 3 7682567 (3) 
ovarian adenocarcinoma 3 9743473 (2), 7614473 (1) 
CITED1 
melanoma 25 11310794 (6), 9683535 (4), 15990678 (4), 11434569 (3)  
nevi 7 11310794 (4), 15990678 (2), 9683535 (1) 
carcinoma papillary thyroid 6 15072698 (6) 
tumor; wilms 4 17710162 (4) 
malignant melanocytic lesion 1 15990678 (1) 
benign thyroid nodule 1 15072698 (1) 
benign nevi 1 15990678 (1) 
amelanotic melanoma 1 9721210 (1) 
follicular tumor 1 15072698 (1) 
tumor initiation 1 17710162 (1) 
TCF21 
neck cancer 2 18398044 (1), 16415157 (1) 
atrioventricular canal 1 9733105 (1) 
growth arrest 1 12493738 (1) 
tumor; wilms 1 12012385 (1) 
lung cancer 2 18398044 (1), 16415157 (1) 
squamous cell carcinoma 1 16415157 (1) 
diabetes; type 2 1 19788433 (1) 
cancer 3 16415157 (2), 18398044 (1) 
PRLR 
breast tumor 44 184919 (3), 177195 (3), 9467590 (2), 7634417 (2)  
97 
 
breast cancer 149 18053149 (6), 18613925 (5), 7639855 (4), 3191209 (4)  
hyperprolactinemia 24 18095129 (4), 8159006 (3), 2986084 (3), 11164823 (3)  
benign breast tumor 3 6145592 (2), 18779591 (1) 
gynecomastia 6 18613925 (5), 11501039 (1) 
prolactin deficiency 2 3008583 (1), 10776642 (1) 
cholestasis 9 16489923 (2), 16461560 (2), 15527411 (2), 15835542 (1)  
cns tumor 4 18095129 (4) 
poorly differentiated thyroid 
carcinoma 2 17525486 (2) 
adenomyosis 4 9126864 (3), 10218134 (1) 
OTC 
hyperammonemia 156 1549234 (4), 683780 (3), 2372929 (3), 19225137 (3)  
otc deficiency 1030 9778587 (7), 9007316 (6), 8857803 (6), 8830175 (6)  
aciduria; orotic 20 3732588 (2), 9266387 (1), 9266354 (1), 8938172 (1)  
reye syndrome 31 893420 (3), 6823424 (3), 175276 (3), 1782015 (2)  
citrullinemia 21 11804205 (3), 18616627 (2), 18562231 (2), 7439194 (1)  
carbamoyl phosphate synthetase i 
deficiency 10 9252147 (2), 7246541 (1), 6724509 (1), 2771513 (1)  
hyperargininemia 12 20004862 (4), 7717428 (1), 7439194 (1), 18616627 (1)  
encephalopathies 29 7666324 (2), 7499756 (2), 18651132 (2), 18414167 (2)  
argininosuccinate lyase deficiency 9 18616627 (2), 18562231 (2), 7717428 (1), 19217439 (1)  
deficiency; enzyme 10 980551 (1), 9048915 (1), 8677801 (1), 8464164 (1) 
OSMR 
primary cutaneous amyloidosis 11 19690585 (4), 18179886 (4), 19663869 (1), 19375894 (1)  
leukemia 10 11602599 (2), 20051625 (1), 18491353 (1), 17979974 (1)  
cervical squamous cell carcinoma 3 17516585 (3) 
cervical squamous intraepithelial 
lesion 2 17516585 (2) 
prolactinoma 2 11095488 (2) 
colon cancer 4 19662090 (4) 
inflammation 7 15893881 (4), 18641356 (2), 18179886 (1) 
adenoma 3 11095488 (3) 
colorectal polyp 1 19223499 (1) 
colorectal cancer 4 19223499 (3), 19662090 (1) 
ITGB6 
squamous cell carcinoma 9 12076695 (3), 12917446 (2), 19528463 (1), 15033492 (1)  
colon cancer 6 11992542 (2), 9705874 (1), 18162155 (1), 15668738 (1)  
emphysema 4 20358620 (2), 12634787 (2) 
oral cancer 3 12917446 (3) 
tumor progression 3 12917446 (3) 
inflammation 6 9761761 (2), 8666675 (1), 18385522 (1), 17200187 (1)  
pocket formation 1 18385522 (1) 
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renal fibrosis 1 17200187 (1) 
alport syndrome 1 17200187 (1) 
pancreatic ductal 
adenocarcinoma 1 15330800 (1) 
CORIN 
cardiac hypertrophy 6 18669922 (2), 18716601 (1), 16054049 (1), 16054020 (1)  
failure heart 10 20061521 (4), 15191894 (3), 15155264 (2), 16054020 (1) 
dfnb24 1 17918732 (1) 
hypertension 12 18716601 (3), 18669922 (2), 16216958 (2), 19131349 (1)  
tapvr 2 11082206 (2) 
sclc 4 14678991 (4) 
dysplasia; epithelial 2 7952341 (2) 
cardiovascular disease 4 17996891 (1), 17485366 (1), 16054020 (1), 11082206 (1) 
hypertensive heart disease 1 15637153 (1) 
myocardial necrosis 1 15659305 (1) 
CLDN3 
ovarian cancer 30 19567823 (4), 15905176 (4), 12855632 (4), 19208807 (3)  
papillary serous carcinoma 9 17326053 (4), 19426958 (2), 18313739 (2), 16725184 (1) 
ovarian tumor 6 19208807 (2), 18057528 (1), 16287068 (1), 15899825 (1)  
atypical hyperplasia 4 17291259 (4) 
increased; permeability 4 16798726 (1), 16275920 (1), 12907427 (1), 12570983 (1) 
cerebral hypoperfusion 3 18782597 (3) 
endometrial cancer 6 18313739 (5), 17326053 (1) 
effusion 5 18439941 (5) 
carcinosarcoma 3 17545541 (3) 
acidosis metabolic chronic 2 17383680 (1), 16675746 (1) 
ADIPOQ 
diabetes; type 2 825 19584347 (7), 17980008 (6), 17010797 (6), 16358955 (6)  
insulin resistance 1748 19755479 (6), 19732605 (6), 19486470 (6), 19302182 (6) 
obese 2059 18253163 (7), 16421343 (7), 16222059 (7), 16092047 (7)  
ovary; polycystic (syndrome) 227 15579189 (11), 19261627 (8), 17562334 (8), 17071536 (8) 
tumor necrosis 557 19462491 (3), 17059516 (3), 20136458 (2), 19539174 (2) 
insulin sensitivity 1102 16286515 (8), 19107128 (7), 16571847 (7), 16373895 (7)  
metabolic syndrome 775 19214966 (11), 16964963 (8), 16755284 (8), 19409756 (7)  
fatty liver 143 15793855 (6), 15579183 (5), 20022856 (4), 19958641 (4)  
hyperinsulinemia 161 19820029 (4), 17893258 (4), 19751297 (3), 16414018 (3)  
nonalcoholic steatohepatitis 77 15718867 (9), 16231364 (6), 19502655 (4), 18923878 (4)  
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